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Bruk av olfaktoriske ensheathing celler, MRI og biomaterialer i transplantasjonsmediert 
reparasjon av CNS skader 
Den beskrevne studien har brukt en interdisiplinær tilnærming for å evaluere transplantasjons mediert 
CNS reparasjon i en skademodell av synsnerven. Ved å integrere forskjellige MRI metoder har vi 
analysert olfaktoriske ensheathing celler’s (OEC) evne til å integrere og overleve in vivo i vår 
skademodell.  Cellenes evne til å modulere regenerasjonen av den skadede synsnerven er også 
dokumentert ultrastrukturelt med elektronmikroskopi (EM). Studien har også omfattet in vitro analyser 
av interaksjonen mellom OEC og modifiserte biopolymerer i 2-og 3-dimensjonale matriser.  
Den spesifikke målsetningen med denne studien har vært: (a) Utvikle protokoller for effektiv merkning 
av OEC med mikron store jern partikler; (b) Kombinere cellulær MRI og mangan-forsterket MRI 
(MEMRI) for spatiotemporal monitorering av intravitreal (ivit) og intra-optisk nerve (iON)
transplantasjon av OEC; (c) Studere celleimplantatenes evne til å promotere regenerasjon av 
synsbane aksoner etter skade i synsnerven både (i) longitudinelt in vivo med MRI og (ii) 
ultrastrukturelt med transmisjons elektron mikroskopi (TEM); (d) Produsere og teste modifiserte 
alginat strukturer som plattformer for kontrollert frigjøring av mangan (Mn2+) brukt som 
kontrastmiddel ved MEMRI; (e) Utvikle arginin-glycin-aspartat (RGD)-peptid alginater og karakterisere 
interaksjonen med OEC dyrket på disse modifiserte aliginat matrisene. 
I avhandlingen presenteres gjennomføringen av disse målene og belyser potensialet av å integrere 
MRI, biomateraler og celleterapeutiske teknologier i studier av transplantasjons-mediert reparasjon av 
skader i CNS.  
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1. Introduction
 
1.1. CNS damage and repair 
 
Damage to the central nervous system (CNS) as a result of trauma or neurodegenerative 
disease, such as Parkinson’s, Alzheimer’s, and Huntington’s disease, multiple sclerosis (MS), and 
amyotrophic lateral sclerosis (ALS), constitutes one of the major causes of morbidity and 
mortality in the human population today, with serious implications for the quality of life of 
millions of people and significant associated socio-economic costs. Yet despite intense research 
effort from translational neuroscientists and clinicians over several decades, CNS regeneration 
after injury still remains elusive. 
 
Research progress over the last decades, has questioned the old dogma of an immutable CNS, 
which, unlike the peripheral nervous system (PNS), lacks the ability to regenerate once 
development has been completed [1]. This dogma is best expressed in the words of the 
pioneering Spanish neuroscientist Santiago Ramón y Cajal:  ‘… the functional specialisation of 
the brain imposed on neurones two great lacunae; proliferative inability and irreversibility of 
intraprotoplasmic differentiation. It is for this reason that, once the development was ended, 
the founts of growth and regeneration of axons and dendrites dried up irrevocably. In adult 
centres the nerve paths are something fixed, ended, immutable. Everything may die, nothing 
may be regenerated’.  However, as Ramón y Cajal himself observed, ‘the incapability of 
regeneration is not a fatally irresistible law, but a secondary outcome of a physical or chemical 
environment unfavourable for the growth of the sprouts’ [1].  This led to the hypothesis that 
CNS axon regeneration should be possible provided that there is a permissive environment 
supporting growth, demonstrated, for the first time, as the intrinsic regenerative capacity of 
axotomised CNS neurons to regrow their axons in the presence of peripheral nerve grafts (PNG) 
[1-4].   
 
These early experiments in the 1980s signified a new era in neuroscience research, 
underpinned by the effort to elucidate the mechanisms of CNS damage and repair and to 
develop appropriate therapeutic interventions aimed at CNS regeneration, with the ultimate 
goal of achieving neuroanatomical restitution and re-establishment of lost synaptic connections.  
It is, nonetheless, the immense complexity of CNS degeneration and regeneration mechanisms 
that renders the development of effective regenerative approaches highly challenging. 
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1.1.1. CNS lesion pathology and axon growth inhibition 
Insult to the CNS results in loss of neurons and/or damaged neuronal axons and the 
consequent disruption of neuronal circuits, leading to neurological deficits which are permanent 
and irreversible.   
 
Neuronal cell death is due to either necrosis, or apoptosis [5-11]. Necrotic cell death occurs as a 
result of anoxia or mechanical damage to the cell membrane, causing severe disruption of 
metabolic mechanisms and cellular homeostasis [8]. On the other hand, neuronal cell death due 
to apoptosis is genetically programmed cell death precipitated, in the case of CNS lesions, by 
extracellular events, such as withdrawal of trophic support, free-radical damage and DNA 
damage [8, 12]. During apoptosis, the cell membrane initially remains intact, while cellular 
components start being digested inside the cell. As the apoptotic cycle progresses, the cell 
membrane  becomes convoluted and cellular fragments separated and subsequently ingested 
by macrophages and other scavenger cells [8, 13]. Excitotoxicity, metabolic imbalance, 
oxidative stress, and calcium influx are events that, depending on the type of CNS lesion, may 
induce cell death via either apoptotic or necrotic mechanisms [14, 15]. Such events are 
determined by intricate molecular mechanisms and affect specific ligands and receptors and 
intracellular and extracellular signalling cascades, with major implications for synaptic 
connectivity and neurotransmission.   
 
The vast majority of CNS lesions invariably affect neuronal axons, whose length of extension 
(i.e. up to 1m) from their somata, makes them highly vulnerable to insult [16].  Following 
axotomy, the distal segment of the injured axon gradually degenerates and becomes 
demyelinated, a process known as Wallerian degeneration [16]. Depending on the distance of 
the lesion from the cell body, axotomy may lead to retrograde neuronal death via either 
apoptotic or necrotic mechanisms, with rapid necrotic death occurring when the neuronal axon 
is damaged close to the soma. Additionally, anterograde cell death as a result of apoptosis may 
occur in target neurons, with which the axotomised neurons form synapses [16]. In all cases, 
trophic support from/to axotomised neurons is disrupted and eventually lost, leading to 
neuronal death [16].  On a molecular level, axotomy induces the upregulation and down-
regulation of a host of different genes, including (i), transcription factors, such as c-jun, jun D, 
Krox-24; (ii), growth-associated proteins, i.e. GAP-43; (iii), cytoskeletal proteins, such as F 
actin; (iv), growth factor receptors and growth factors, including the tyrosine kinase (trk) family 
of receptors for brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), nerve growth 
factor (NGF), and its low affinity receptor, p75NTR; (v), cytokines, including interleukins (i.e. IL-
2
6, IL1ǃ), and tumour necrosis factor (i.e. TNFĮ); as well as (vi), the myelin-associated inhibitors 
NogoA, myelin-associated glycoprotein (MAG), and oligodendrocyte myelin glycoprotein (OMgp) 
[16-25].   
 
Apart from mechanical damage to axons at the lesion site, with subsequent disruption of the 
neuronal circuitry and gradual degeneration of the affected neurons, CNS lesion pathology is 
further complicated by a cascade of secondary cellular and molecular events which evolve up to 
several weeks after the injury. These include an inflammatory response with microglia 
activation, as well as macroglia responses, characterised by reactive astrocytosis, infiltration by 
oligodendrocyte precursors (OPCs), and the formation of the glial scar [26-34] (Figure 1.1).  
 
 
 
Figure 1.1 – Pathological features of CNS injury. Illustration showing process of demyelination, 
reactive astrocytosis, and glial scar formation after CNS axotomy. 
 
Microglia are immune-competent cells intrinsic to the adult CNS [35]. In response to CNS injury, 
resident microglia within the CNS parenchyma, become activated and are recruited to the lesion 
site within minutes, followed in the next few days by proliferation of macrophages and 
lymphocytes [16, 34-36].  Additionally, in injuries that damage blood vessels and result in 
extensive haemorrhage, there is massive macrophage infiltration from the blood, as well as 
some neutrophil recruitment, which, however, is limited given that the Į-chemokines involved in 
the recruitment of leukocytes are absent in the CNS [16, 32, 35, 37].  Microglia assume 
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phagocytic  and macrophage-type roles in response to the presence of cellular and myelin 
debris, however, as a result of the fact that microglia/macrophage populations in the injured 
CNS are much smaller than in the PNS, clearance of such debris in the CNS is significantly 
slower [16, 32].  Furthermore, activated microglia accumulate around the cell body of injured 
axons whose input synapses have withdrawn, and remain there for several weeks [34].  When 
the microglia subsequently retract, they are replaced by astrocytes, which become interposed 
with the neuronal terminals and cell body, effectively blocking re-innervation [16, 34].  
 
Mechanical disruption of the lesion microenvironment inadvertently results in astrocytic death 
[38]. Moreover, in response to injury, surviving astrocytes in the lesion area become reactive, 
leading to a series of biochemical changes, including elevated levels of glial fibrillary acidic 
protein (GFAP), cytoskeletal changes and upregulation of nestin and vimentin production,  as 
well as changes in the levels of cytokines, proteases and protease inhibitors, cell surface matrix 
and other molecules [29, 39-45].  In the event of injury that penetrates the meninges, 
interactions between reactive astrocytes and invading meningeal cells affect the process of 
gliosis and the re-formation of the glia limitans, in which meningeal cells form a layer around 
the inside of the injury, preventing molecular diffusion [29, 46-48].  The resulting tissue, 
described as the ‘glial scar’, is densely packed with hypertrophic astrocytes with interdigitating 
processes [16], extracellular matrix (ECM), and gap and tight junctions [16, 32]. In addition to 
astrocytes, macroglia responses to CNS injury include the recruitment of oligodendrocyte 
precursors to the lesion. OPCs express growth inhibitory molecule NG2 as well as other 
chondroitin sulphate proteoglycans (CSPGs). A host of CSPGs, including tenascin-R, tenascin-C, 
neurocan, versican, brevican, and phosphacan are also expressed in the ECM, as well as in 
reactive astrocytes and neurons at the lesion site [16, 32, 49-66]. As a result, intricate 
interactions between cellular and molecular constituents of the injury microenvironment pose a 
physical and chemical barrier to regenerating CNS axons and migrating myelinating cells.   
 
In addition to the extrinsic factors described above, a major complicating factor in CNS axon 
growth after injury is the upregulation of a host of axon growth inhibitory molecules of the 
semaphorin (Sema), ephrin, and netrin families and their respective receptors [50, 67-74].  
These ligands and receptors are axon guidance molecules that regulate pathfinding and 
chemotaxis and mediate synapse selection during development [50, 67].  Interestingly, in the 
adult CNS, the same ligands and receptors are implicated in mediating plasticity and stabilising 
synaptic connections [50].  Upregulation of expression of inhibitory ligands and receptors in 
reactive glia and fibroblasts in the lesion microenvironment triggers downstream signalling 
cascades in the Rho family of small GTPases, including RhoA, Cdc42, and Rac1, which regulate 
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the actin cytoskeleton, change the motility of outgrowing neurons, and thus arrest neurite 
outgrowth by inducing growth cone repulsion or collapse [50, 75, 76]. Finally, intrinsic factors 
such as reduced plasticity associated with neuronal maturity, as well as changes in 
evolutionarily conserved molecular mechanisms, for example, the PTEN-dependent inactivation 
of the mTOR pathway that promotes axon extension in CNS neurons, greatly impinge on the 
capacity of the adult CNS to regenerate after injury [77-81].   
1.1.2. CNS recovery: mechanisms and strategies 
Ability to promote CNS recovery after injury is contingent on a multitude of factors, including 
the nature, extent and location of the insult, as well as the time elapsed between the insult and 
the therapeutic intervention [80].  At the early stages after injury, damaged CNS neurons enter 
a programme of abortive regeneration [81-83]. The degree of spontaneous axonal sprouting in 
these cases is dependent on neuronal cell subtype and maturity, while neurite outgrowth is 
often aberrant, extends over short distances and, consequently, lacks the ability to promote 
axon regeneration towards correct synaptic targets distal to the lesion [81, 82]. Furthermore, 
collateral sprouting from the terminals of intact neurons, or the proximal segment of injured 
mature CNS axons is marginal and thus unlikely to effectuate repair of neuronal circuits via 
compensatory routes [81].   
 
As discussed earlier, the regenerative failure of CNS axons can be attributed to interplay 
between intrinsic and extrinsic factors. Hence, therapeutic strategies may target either 
endogenous or exogenous constituents of CNS lesion sequelae or, alternatively, involve 
combinatorial approaches addressing both. Such strategies must be able to meet a number of 
challenges, mainly: (i), stimulate robust neurite outgrowth, (ii), circumvent the chemical and 
physical barriers posed by the non-permissive CNS neuropil to promote sustained growth cone 
advance through it, and (iii), achieve restitution of lost synaptic connections with functional 
outcome.  
 
One approach to CNS recovery is limiting neuronal cell death by adopting neuroprotective 
strategies which aim to reduce excitotoxicity, metabolic imbalance, and oxidative stress after 
injury [14]. Such approaches may include pharmacological modulation of calcium influx using 
NMDA antagonists/calcium blockers, administration of free-radical scavenging agents, 
promotion of cellular metabolic activity, and use of anti-apoptotic and anti-inflammatory 
treatments [14, 84-93]. The latter aim to limit secondary damage by preventing extensive 
cavitation and gliosis. It  is noteworthy, however,  that in certain circumstances, inflammation 
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may actually exert a neuroprotective effect on lesioned CNS neurons, as demonstrated by 
increased neurite outgrowth induced by lens injury and zymosan injections after visual pathway 
lesion [94-98]. 
 
In addition to the above, infusion with neurotrophic factors, including BDNF, NT, glial cell line-
derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNTF), fibroblast growth factor 
(FGF), transforming growth factor (i.e. TGFǃ), and neurturin, may prevent axonal death and/or 
promote anatomical and biochemical plasticity in target CNS neurons [97-108]. Another 
approach is overcoming the inhibitory nature of the lesion microenvironment. This may be 
effectuated by modulation of the molecular and/or cellular components of axon growth 
inhibition. Examples include the use of neurotrophic factors, antibodies/recombinant protein 
treatments, and gene therapy to neutralise/modulate the expression of CSPGs [109-114], 
myelin-associated inhibitors [115-121], and axon guidance molecules [122-124], and to 
influence specific signalling cascades and signal transduction mechanisms [79, 122, 125-131].  
 
Such interventions have varying degrees of success, but overall fail to achieve significant or 
sustainable functional outcomes. Furthermore, the complexity of CNS lesion pathology and body 
of experimental evidence strongly suggest that better results are to be derived by applying 
combinatorial approaches, rather than individual treatments [81, 132-135].  Furthermore, while 
some treatments yield promising results, they may not be clinically applicable. One such 
example is conditioning lesion of the peripheral branch of dorsal root ganglia (DRG) in the form 
of sciatic nerve injury, prior to spinal cord or dorsal column lesioning, to promote regeneration 
of centrally ascending afferent fibres [136-139].   
 
1.1.3. Transplant-mediated CNS repair 
One of the underlying assumptions in many CNS repair strategies is that regeneration may be 
achieved by recapitulation of normal neuronal development, i.e. that CNS neurons may be 
induced to switch to genetic programmes characterised by enhanced plasticity and regenerative 
capacity [140]. Thus the success of neuroprotection, neuronal replacement, stimulation of 
axonal sprouting and synaptogenesis, myelination, as well as de novo neurogenesis may be 
contingent on recapitulation of the relevant developmental mechanisms. Treatment of CNS 
lesions utilising tissue and cell transplants largely reflects this rationale.   
 
As it was mentioned at the beginning of Section 1, the old dogma suggesting that the mature 
CNS is characterised by complete lack of regenerative capacity was challenged for the first time 
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when Aguayo and colleagues demonstrated that large numbers of lesioned dorsal root ganglia 
(DRG) and spinal cord neurons are able to extend axons into peripheral nerve (PN) segments 
engrafted into the injured rat spinal cord [1-4]. In later experiments, Aguayo and colleagues 
showed that intra-optic nerve (iON) PNG promote robust retinal ganglion cell (RGC) axon 
regeneration and re-innervation of the superior colliculus after visual pathway lesion in the adult 
rat [141, 142]. Similarly, Berry and colleagues demonstrated that intravitreal (ivit) PNG 
promotes RGC axon regeneration through the rat optic chiasm and into the optic tract [143, 
144].  Additionally, a number of other studies demonstrated the neuroprotective and 
myelinating effects of Schwann cell-containing PNG alone, or in combination with other 
strategies, such as administration of neurotrophins and chondroitinase ABC [145-155]. The 
main limitation in such approaches, though, is that regenerating CNS axons growing through 
PNG generally fail to exit the Schwann-cell microenvironment of the graft and make the 
transition into the CNS [156]. In the same manner, regenerating sensory afferents from 
damaged DRG do not cross from the PNS into the CNS, but stop at the dorsal root entry zone 
(DREZ) [156]. Nonetheless, CNS axon regeneration through PNG into the distal spinal cord 
segment with partial restoration of functional recovery has been reported [155]. However, this 
promising outcome is largely attributed to additional manipulation of the non-permissive lesion 
microenvironment with FGF-1, rather than to the PNG alone [155-158]. 
 
Another transplantation strategy utilises foetal tissue for neuronal replacement and 
neuroprotection in experimental spinal cord and brain lesions.  Foetal spinal cord transplants 
have been shown to promote functional recovery and to restore lost supraspinal and 
serotonergic input after spinal cord injury in the adult rat [157, 159, 160]. Again, improved 
effects were achieved in cases when foetal transplantation was combined with other strategies, 
including administration of BDNF, and NT-3 [161, 162]. 
 
Apart from transplantation of tissue segments, embryonic stem cells (ESCs), neural stem cells 
(NSCs)/neural progenitor cells (NPCs), and glia are attractive candidates for transplant-
mediated CNS repair. Pluripotent ESCs are characterised by unlimited expandability and 
differentiation capacity [163, 164]. OPCs derived from human ESCs (hESCs) have been used to 
treat spinal cord injury patients in Phase I clinical trials with promising results [165-167]. 
However, the use of hESCs, is fraught with ethical concerns [168-170].  Furthermore, the 
pluripotent character of ESCs harbours the potential for aberrant growth after implantation into 
the host nervous system, resulting in overgrowth and formation of tumours, like teratomas 
[171]. Moreover, the use of ESC allografts carries the inherent risk of transferring viral, 
bacterial, fungal, and prion contaminants from the donor to the host [172, 173]. Finally, the risk 
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of rejection of tissue allografts necessitates the administration of immunosuppressive 
treatments, which may potentially precipitate side-effects and/or complications [173].   
 
Mulipotent NSCs and neural stem cell progenitors (NSPs) are self-renewing mitotically-active 
cells harvested from special CNS locations in which neurogenesis is ongoing throughout adult 
life. These NSC niches include the subventricular zone (SVZ) of the lateral ventricle, and the 
subgranular zone (SGZ) of the hippocampal dentate gyrus [174-179]. Alternatively, NSCs can 
be derived from induced pluripotent stem cells (iPSCs) [180-184].  NSCs/NPCs give rise to cells 
of neural lineage, i.e. neurons, astrocytes, and oligodendrocytes, via asymmetric division [179]. 
These stem cell populations have been utilised to treat neurodegenerative conditions such as 
experimental ALS, Parkinson’s disease, and spinal cord lesions with promising results [185-195]. 
However, for safe translation of NSC-based therapies into the clinics a number of obstacles will 
need to be overcome, including the limited availability and expandability of human NSCs 
(hNSCs), genetic and epigenetic instability, tumorigenic potential, and other unwanted effects 
of NSC transplants, such as allodynias and dyskinesias [140, 157, 196-204]. 
 
1.2. Olfactory ensheathing cells in transplant-mediated CNS repair 
1.2.1.  Olfactory ensheathing cell properties and function 
The observation, in the late 1970s, by Graziadei and Monti Graziadei that neurogenesis in the 
olfactory system continues throughout adult life and that mature olfactory receptor neurons 
(ORN) regenerate their axons and establish functional connections after injury [205-216] 
suggested that olfactory ensheathing cells (OECs), the glia that enwrap olfactory axons [217, 
218], are possible candidate cells in transplant-mediated CNS repair.  
 
OECs are a unique type of glia first identified by Golgi [219] and Blanes [220, 221]. OECs are 
found both in the olfactory epithelium and olfactory bulb (OB) of the primary olfactory system. 
The OECs that are located in the lamina propria of the nasal cavity associate closely with 
afferent receptor bundles of ORN, while intracranially, OECs enfold large numbers of 
contiguous, unmyelinated axons of the first cranial nerve [218, 222-235] (Figure 1.2). 
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 Figure 1.2 – OECs enwrap ORN along their trajectory from the PNS into the CNS; BV: blood 
vessel; BG: Bowman gland. 
 
 
During mammalian development, ORN axon pathfinding and elongation in the lamina propria is 
partially attributed to chemotactic and mechanical support provided by OECs [236, 237]. OECs 
facilitate elongation and fasciculation of developing ORN axons by expression of cell adhesion 
and ECM molecules such as NCAM, E-NCAM, L1, collagen IV, galectin-1, and ǃ2-laminin [236-
241]. OECs migrate in tandem with developing ORN axons across the lamina propria and 
provide directional guidance during axon tract formation [236, 237]. Furthermore, p75NTR-
expressing OECs contribute to the formation of the glia limitans of the OB [241, 243], while at 
the ventral olfactory nerve layer (ONL), OECs guide ORN axons towards the olfactory bulb 
glomeruli by differential expression of galectin-1, ǃ2-laminin, and Sema3A [236, 240].  
 
ORN transmit odour signals from the olfactory mucosa to the OB, from where the signals are 
subsequently relayed to the olfactory cortex [244, 245]. It is established that detection and 
response to odours is crucial for the behaviour and survival of many species. This suggests that 
the continual turnover and regeneration of ORN in the primary olfactory system safeguards 
olfactory integrity against noxious stimuli [244]. Damage to the olfactory epithelium (OE) 
stimulates proliferation and differentiation of resident putative stem cells, i.e. horizontal basal 
cells (HBCs) and globose basal cells (GBCs) into ORN, while normal ORN turnover is attributed 
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solely to GBCs [244, 246, 247].  OECs provide distinct guidance cues and facilitate elongation of 
newly generated ORN axons along their trajectory, from the PNS into the CNS and OB, where 
the ORN establish synapses with second order neurons [217, 229, 248-250].  
 
The localization, function and role of OECs in primary olfactory system development, adult 
neurogenesis and regeneration suggested that OECs are indeed stem cells [251]. Despite 
morphological and antigenic plasticity, however, OECs seem to lack pluripotency and ability for 
continuous self-renewal [244]. On the other hand, apparent similarities between OECs, 
Schwann cells, and also astrocytes have led to a degree of discrepancy in the relevant 
literature, with OECs often being identified as Schwann cells or astrocytes, especially in earlier 
publications [235, 251-254].   
 
1.2.2. Comparison of OECs with Schwann cells and astrocytes 
 
OECs display a malleable morphological and molecular phenotype and share many similarities 
with immature non-myelinating Schwann cells, as well as astrocytes both in vitro and in vivo 
[229, 245, 254-261].  Morphologically, OECs appear either spindle-shaped or stellate-shaped, 
closely resembling Schwann cells and astrocytes, respectively [256].  This heterogeneity is also 
reflected in the antigenic expression of OECs. In the early stages after isolation and culture, 
OECs express p75NTR, a molecular marker also expressed by Schwann cells [221, 255]. 
However, in vivo p75NTR expression in both OECs and Schwann cells is low, but becomes 
upregulated in response to ORN and PN injury, respectively [221, 255, 260]. Furthermore, OECs 
expressing p75NTR are spindle-shaped and stain positive for the glial marker O4, but express no 
galactocerebroside (GalC) [255, 260], while stellate-shaped OECs are PSA-NCAM positive [221, 
254, 255, 260].  Moreover, both OECs and Schwann cells express peripheral myelin protein P0 
[261, 262]. This overlap in antigenic expression and morphology makes it difficult to distinguish 
OECs from other glia, especially Schwann cells.  
 
A recent report by Boyd et al [263] claimed that calponin, an actin-binding protein, can be used 
as a marker to unequivocally distinguish OECs from Schwann cells both in vitro and in vivo. 
However, a different study by Ibanez et al [264] challenged this finding as the authors 
concluded that calponin is not expressed by OECs, but rather by fibroblasts and meningeal cells 
in the olfactory mucosa and olfactory bulb, respectively. Tomé et al [265] investigated whether 
the discrepancy in these findings could be attributed to differences in methodology or the 
developmental age of the OECs utilized in the studies [265] and showed that while calponin is 
expressed by subpopulations of connective tissue cells in the neonatal olfactory mucosa, OECs 
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do not express calponin either in vitro or in vivo, irrespective of methodology or developmental 
age [265]. It is, therefore, concluded that calponin is not a specific marker for OECs [265]. 
 
Despite the fact that OECs share common characteristics with other glia, they are a 
developmentally and functionally distinct cell type [248]. The general consensus is that OECs 
originate in the olfactory placode, as opposed to Schwann cells, which originate in the neural 
crest [235, 266]. It was recently claimed, however, that OECs are derived from the neural crest, 
which might potentially enable treatment of human patients by isolating autologous neural crest 
derived stem cells and directing their differentiation into OECs in vitro [267]. Although a shared 
origin between OECs and Schwann cells might explain the many similarities between the two 
types of glia [267], more research might be necessary to confirm and explore these findings.  
 
Irrespective of ontogenic profile, a main distinction between OECs and Schwann cells is the fact 
that they display very different interaction profiles when co-cultured with astrocytes, as 
demonstrated by confrontation assays [268]. OECs intermingle with astrocytes in vitro, unlike 
Schwann cells, which induce boundary formation and a hypertrophic response [221, 268]. 
Similarly, transplanted OECs, not Schwann cells, intermingle with astrocytes in vivo, while 
increased deposition of CSPG by astrocytes is observed in response to Schwann cells only [269-
277]. The exact mechanisms of the interactions of OECs and Schwann cells with astrocytes 
remain to be elucidated, however a number of different molecules, such as CSPG, ephrins, 
FGF2, and N-cadherin, are involved [221, 270-272]. Finally, in vitro assays demonstrated 
distinct interactions of OECs and Schwann cells with meningeal cells [278]. In a manner similar 
to that characterizing interactions with astrocytes, OECs intermingle with meningeal cells, as 
opposed to Schwann cells, which aggregate into clusters [278]. 
 
1.2.3.  OEC transplants as mediators of CNS repair 
 
The distinct interactions of OECs and Schwann cells with astrocytes and meningeal cells are 
highly relevant with regard to the capacity of either glia to promote CNS axon regeneration by 
negotiating the non-permissive chemical and physical boundary of the glial scar. Furthermore, 
the rich antigenic profile and ability of OECs to support continual ORN outgrowth throughout 
adult life render them superior candidates for transplant-mediated CNS repair.  
 
OECs have been transplanted in different spinal cord injury models, including electrolytic and 
photochemical lesions, dorsal column lesions, complete spinal transection, contusion injury, and 
dorsal rhizotomy [277]. Each lesion paradigm is characterized by different cellular, molecular, 
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anatomical and functional sequelae, thus the inherent assumptions in the use of OECs, and also 
the mechanisms that determine transplant-mediated outcomes are quite different in each case 
[248, 277, 279]. OECs have been reported to repair lesion cavities and to promote axon 
regeneration of corticospinal, dorsal column, and monoaminergic neurons [248, 280-284]. 
However, a number of subsequent studies failed to confirm OEC-mediated axon regeneration 
through and beyond the lesion in some of these models [248, 277, 285-291]. Nonetheless, 
combinatorial approaches significantly enhance the regenerative effects of OECs in some of 
these lesions [248]. Examples include long-distance axon regeneration beyond the lesion site 
mediated by (i), transplanted OECs combined with stimulation of neuronal cell body with cAMP 
and injured axons with neurotrophins [292], and (ii), OEC engraftment in combination with 
fibroblasts and biomatrices [293]. Apart from the above, OEC transplantation after dorsal 
rhizotomy promoted entry of DRG axons into the DREZ and dorsal horn of the spinal cord [277, 
294]. Furthermore, Li and colleagues [295] showed regeneration of afferent DRG axons across 
the DREZ. This led to the formulation of the ‘pathway hypothesis’ [295] , which proposes that 
transplanted OECs interact with astrocytic processes to form pathways that bridge CNS lesions, 
thus rendering the lesion microenvironment permissive to axonal growth [277, 295] (Figure 
1.3). However, while modulation of the lesion microenvironment by transplanted OECs after 
dorsal root injury was confirmed by other groups, these investigators did not find evidence of 
axon regeneration [277, 296]. As a result, it has been suggested that OECs promote axon 
regeneration only in cases of homodirectional OEC and sprout-like axon (SLA) migration [277, 
294, 297].  
 
In addition to the above, a number of studies have reported functional recovery promoted by 
OEC transplants in different types of spinal cord lesions [298-304]. For example, OEC 
transplantation after electrolytic corticospinal tract lesion at the upper cervical level in rats 
promoted functional outcome by partially restoring skilled forepaw movement [298] while, after 
spinal cord contusion injury, OEC transplants promoted sparing of supraspinal axons and 
improvement of hindlimb function [304]. Overall, however, OEC-mediated functional outcomes, 
as assessed by behavioural tests, appear to be variable [285, 298, 299, 301, 304-306]. Toft et 
al [303] used electrophysiology for direct measurement of changes in the activity of spinal 
neurons in response to OEC transplantation after injury and found evidence of increased 
synaptic activity in the zone of partial preservation compared to that of corresponding sensory 
afferents in untreated animals [248, 303]. Given that rat motoneurons associated with walking 
retain considerable autonomic activity when disconnected from supraspinal centres [248], the 
findings by Toft et al [303] indicate that the additional functional outcomes observed after OEC 
transplantation involve responses in local neuronal networks at spinal levels below the site of 
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the injury [248]. In addition to promoting functional outcome after spinal cord injury (Figure 
1.4), OECs have been reported to increase the dendritic length of sympathetic preganglionic 
neurons above the injury [307], reduce the duration of autonomic dysreflexia [307], and also 
mitigate neuropathic pain, including tactile allodynia, and thermal hyperalgaesia [308]. 
 
 
 
 
Figure 1.3 – Illustration showing reparative effects of OECs after CNS axotomy. Transplanted 
OECs fill the lesion cavity and modulate the lesion microenvironment through interactions with 
astrocytes, while they promote CNS axon regeneration and remyelination.  
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Figure 1.4 – Illustration showing axon regeneration and functional recovery promoted by 
transplanted OECs. OECs secrete soluble factors, stimulate angiogenesis, and provide trophic 
support to regenerating CNS neurons, leading to re-establishment of lost synaptic connections 
distal to the injury site. 
 
 
The reparative potential of OECs has also been demonstrated in different models of brain 
lesions. OEC showed promising integration and promoted growth of axons in the septal-
hippocampal pathway after fimbria-fornix pathway lesion [309], enhanced neuronal plasticity 
after stroke [310], and restored dopamine innervation and functional deficits in a rat 
Parkinson’s disease model when co-transplanted with ventral mesencephalic cells  [311, 312]. 
Moreover, several in vitro and in vivo studies showed that OECs play an important role in 
neuronal support, survival [313, 314], and differentiation [315-317]. Finally, the synergistic 
effects of OECs and NSCs in mediating CNS axon regeneration and functional recovery have 
been demonstrated in a number of co-transplantation studies [314, 316, 318]. The above 
effects are attributed to secretion of a host of different neurotrophic factors and cell 
adhesion/ECM molecules by OECs, including BDNF, GDNF, N-CAM, claudins, cadherins, and 
catenins [313-318].   
 
Much of the interest in OECs as reparative candidates in CNS lesions stems from their similarity 
with non-myelinating Schwann cells and ability to assume a myelinating phenotype and produce 
peripheral type myelin upon association with large diameter axons [319-325].  As discussed 
14
earlier in this chapter, CNS axotomy induces axon and myelin loss as part of the process of 
Wallerian degeneration [16]. Additionally, demyelination occurs as a result of oligodendrocyte 
damage and inflammatory disease, such as MS [320]. Demyelinated axons are characterized by 
impaired conductivity leading to neurological deficits [320]. While remyelination may occur as 
part of a spontaneous regenerative response, the myelin sheaths are not fully restored [326] 
and, in the case of MS and experimental autoimmune encephalomyelitis (EAE), remyelination is 
not robust enough to mediate significant and/or sustainable functional outcomes [320, 326]. 
Thus remyelination mediated by cell transplants aims at neuroprotection, and alleviation of 
functional deficits by restoring myelin sheaths and re-establishing rapid saltatory conduction 
[320, 326].  Although Schwann cell transplants can remyelinate CNS axons, their myelinating 
efficacy is often impaired in the presence of astrocytes [320, 327]. Therefore, the distinct ability 
of OECs to intermingle with astrocytes [268-270, 277] suggested that OECs, rather than 
Schwann cells, should be utilised in the treatment of demyelinating CNS lesions [248, 320]. A 
number of studies have demonstrated remyelination of demyelinated CNS axons promoted by 
OEC transplants in different CNS lesion models [283, 321-324, 328, 334]. However, myelination 
by OECs is indistinguishable from that mediated by Schwann cells [319-325]. Thus, in the 
absence of a specific marker for OECs [264-265], these results should be interpreted with 
caution, especially in cases when Schwann cell invasion into the lesion site cannot be excluded 
[327]. Furthermore, experimental evidence suggests that the myelinating capacity of OECs can 
be enhanced in the presence of non-myelinating cell types, such as meningeal cells [320]. 
 
Finally, a pertinent issue in OEC-mediated CNS repair is the extent to which the therapeutic 
interventions described above are clinically translatable. Barnett et al [332] identified human 
OECs (hOECs) with ability to remyelinate demyelinated axons in a rat spinal cord injury model. 
Other studies have also confirmed the reparative potential of hOEC transplants in experimental 
CNS lesions in terms of promoting remyelination [334] and reducing the volume of the lesion 
cavity [335]. A promising role for hOECs has also emerged from the first clinical applications, 
including a PhaseI/IIa clinical trial [336-338], which demonstrated the feasibility and safety of 
autologous OEC transplantation in paraplegic patients [337, 338]. However, given the small 
numbers of patients involved, these results are considered preliminary and are treated with 
cautious optimism [336-338]. A large scale clinical trial in China has also reported positive 
outcomes of OEC-based therapies in the treatment of human spinal cord injury [339], however, 
an independent observational study challenged these findings as it revealed serious 
inadequacies in terms of application of inclusion-exclusion criteria, correlation of injection sites 
to the level of injury, reporting of complications, correct identification of cell type for 
transplantation, and conformity to international standards pertaining to the safety and efficacy 
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of clinical trials [340]. Moreover, experimental treatment of ALS patients using hOEC transplants 
in Beijing has come under severe criticism given that follow-up of these patients failed to find 
evidence of recovery and also identified serious debilitating side-effects of the treatment [341-
342].  Despite these highly controversial cases, it is widely recognised that OECs hold great 
promise as reparative candidates in transplant-mediated CNS repair. Nevertheless, it is 
generally agreed that further elucidation of the reparative role of OECs in experimental CNS 
injury models is required before safe translation of experimental therapies into the clinics.  
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1.3. OECs in transplant-mediated repair of visual pathway lesion 
1.3.1. The mammalian central visual system 
 
The central visual system is part of the brain and includes the eye, retina, and retinofugal 
projection [343, 344]. RGC neuron somata are located in the retina, while RGC axons exit the 
retina at the optic nerve (ON) head, become myelinated at the lamina cribrosa, and form 
bundles inside the optic nerve (ON) [343, 344] (Figure 1.5). The ON, which is surrounded by 
meninges and cerebrospinal fluid (CSF), passes through the orbit, and optic foramen, into the 
cranial cavity [343, 344]. Immediately rostral to the pituitary gland, the left and right ON 
decussate at the optic chiasm, and form the optic tracts, which subsequently project to the 
lateral geniculate nucleus (LGN), superior colliculus, and midline pretectal area [343, 344] 
(Figure 1.6). Each of these areas mediates visual perception, visually guided movement, and 
pupillary reflexes by relaying information to the neocortex, motor nuclei in the brainstem and 
cord, and brainstem ocular autonomic and motor nuclei, respectively [344]. 
 
 
 
Figure 1.5 – Cross-section of the eye showing key anatomical features.. 
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Figure 1.6 – Illustration showing the mammalian visual pathway. In rodents, 90% of RGC axons 
decussate at the optic chiasm and form the contralateral optic tract.  
 
 
1.3.2. Visual pathway damage and repair 
The rodent visual system is an excellent model for the study of CNS damage and repair, both in 
terms of clinical relevance, and anatomical and biological properties. Loss or impaired function 
of RGC neurons results from direct trauma or ischemia, as well as different types of chronic 
ophthalmic conditions related to diseases such as glaucoma and diabetes [345, 346]. 
Furthermore, various inflammatory and neurodegenerative diseases often present with 
demyelinating ON pathologies, for example, optic neuritis is a common symptom in MS [345]. 
In addition to the above, the special anatomy of the visual pathway, i.e. the exclusively 
centripetal direction of the RGC axon projection, absence of interneurons, and relative 
accessibility of the ON, vitreous body (VB), and retina allow targeted therapeutic interventions 
uncomplicated by inadvertent damage to surrounding neuroanatomical structures [344].  
18
 RGC can be axotomised at different distances from the cell body by means of intraorbital or 
intracranial ON crush (ONC) or transection [148, 347-349]. The cellular and molecular 
responses to ON injury are characteristic of those observed in other types of CNS lesions [344]. 
Following intraorbital axotomy, rapid apoptotic RGC death commences at 5-7 days post-injury 
(dpl) and results in 85-90% RGC loss by 15-20dpl [344, 350-352].  Concomitantly, a host of 
different factors and signaling cascades undergo dynamic changes, including upregulation of c-
jun [353], CNTF receptor Į (CNTFRĮ) [354], trk receptor [355], BDNF [355], GDNF [356], N-
CAM [357], and GAP-43 [358], as well as transient upregulation of Sema3A [359], and 
downregulation of the netrin family receptors DCC, Unc5H1, and Unc5H2 [345, 360].  The glial 
scar is formed by 8dpl, and subsequently matures and contracts at 8dpl-18dpl [344]. In 
addition to the above, RGC axons at the proximal ON segment respond to the injury by entering 
a programme of abortive regeneration, in which sprouting RGC axons do not cross the lesion 
site and their growth is arrested by 20dpl [344].  
 
Despite the fact that RGC axon regeneration is inhibited in a manner typical of other CNS 
lesions, the rodent ON injury model is one of the few models where robust axon regeneration 
has been achieved after therapeutic intervention [81, 135, 143, 144, 344, 361, 362], including 
activation of inflammatory cytokines [81, 94, 95, 97, 147, 362-364], ivit  PNG [143, 144, 365], 
ivit administration of neurotrophic factors [135], as well as activation of the mTOR pathway 
[77-79, 127, 366]. Such strategies aim to promote RGC survival, stimulate axonal sprouting, 
and disinhibit RGC axon growth by neutralizing inhibitory ligands and signaling cascades, 
including Nogo, NgR1, epidermal growth factor receptor (EGFR), RhoA, and ROCK [344].  
 
As discussed earlier, the glial scar around the injury site presents a physical and chemical 
barrier to regenerating CNS axons. Interestingly, though, in regenerating ON injury models in 
which RGC axons grow beyond the lesion site, anti-scarring treatments may not always be 
necessary [143, 144, 344]. Recruitment of fibrinogen to the lesion in the acute haemorrhagic 
phase of CNS scarring, activates RhoA-mediated inhibition of neurite outgrowth and causes 
growth cone collapse via formation of a fibrinogen/integrin/EGFR complex [344, 367]. TGFǃ 
neutralisation reduces scar deposition and inhibits infiltration by meningeal fibroblasts to the 
lesion site [344], nevertheless, it does not prevent axon growth arrest given that myelin-
associated inhibitors and GSPGs are still secreted by reactive glia [50, 344].  However, as 
demonstrated by Berry et al [143, 144], in regenerating ON lesion models fibrotic scarring is 
significantly reduced, even when fibrinogen influx is not inhibited. This suggested that 
regenerating RGC axon growth cones modulate their microenvironment by secretion of matrix 
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metalloproteinases (MMPs) which, in turn, induces MMP secretion by ON glia [132, 344, 368], 
thus disinhibiting axon growth and blocking migration of meningeal fibroblasts [344, 368]. It 
follows that, as long as a therapeutic strategy can promote robust RGC axon regeneration, 
which can effectively regulate growth inhibition, additional anti-scarring treatments may be 
redundant [344]. 
1.3.3. OECs in visual pathway repair 
 
As discussed earlier, central visual pathway damage and repair are determined by the same 
mechanisms involved in degeneration and regeneration of other types of CNS lesions. As a 
consequence, successful strategies for visual pathway repair should not only address the issue 
of RGC neuron survival, but should also aim to induce RGC axons to enter a rigorous growth 
state, promote their growth through the inhibitory lesion microenvironment, direct them 
towards the right synaptic targets, remyelinate them and, ultimately, restore synaptic function. 
Key attributes of OECs render them particularly interesting in this context. These include: (i), 
secretion (natural and engineered) of a multitude of neurotrophic factors, such as BDNF, GDNF, 
CNTF, and NT4/5 [233, 285, 286, 317, 346]; (ii), superior ability to intermingle with astrocytes 
and meningeal cells and to modulate CSPG expression [268-278]; (iii), production of MMP2 
[370] and expression of cell adhesion and ECM molecules [236-241]; (iv), remyelinating 
capacity [261, 262, 283, 321-324, 328, 334]; and (v), ability not to interfere with retinal target 
recognition [346, 371, 372].  
 
Repair of visual pathway lesions using OEC transplants is an emerging field in neuroscience. As 
a result, there are currently only few studies that have explored the reparative potential of 
OECs after RGC axotomy. Li et al [373] transplanted a mixture of OECs and olfactory nerve 
fibroblasts (ONF) embedded in a matrix into the lesion site of the transected rat ON and 
showed RGC axon growth 10mm into the distal stump. In a later study, the same group 
reported myelination of the damaged ON by Schwann cells, but not by OECs [374].  Wu et al 
[375] showed improved survival of axotomised RGC at 7dpl after intraoptic OEC engraftment, 
however, they did not find evidence of improved RGC survival at 14dpl. Furthermore, Liu et al 
[376] reported long-distance RGC axon regeneration and functional recovery at 8 weeks post-
lesion (wpl) after combined treatment with OECs and human recombinant GDNF. Finally, Plant 
et al [346] transplanted purified OECs transduced with LV-CNTF at 5dpl after ONC injury and 
showed RGC axon growth beyond the lesion site at 7wpl, but found no surviving OECs in the 
ON at the specific time point.  
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While these findings are very important in highlighting the potential and, perhaps, the 
limitations of OECs as mediators of visual pathway repair, it is clear that the relative novelty of 
the specific line of research provides amble opportunity for further investigation for the purpose 
of eliciting key mechanisms of OEC-mediated recovery, optimizing/controlling the viability and 
function of transplanted OECs in situ, and developing therapeutic strategies that can be 
translated into clinical applications for the treatment of different types of CNS lesions in the 
future.  
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 1.4. Monitoring transplant-mediated CNS repair by MRI 
A pertinent issue in translational neuroscience is the ability to monitor anatomical, biochemical, 
molecular, and functional changes mediated by therapeutic interventions in a serial, non-
invasive manner.  Magnetic resonance imaging (MRI) is highly-relevant in this context. 
 
1.4.1. Manganese-enhanced MRI (MEMRI) 
MEMRI utilises the paramagnetic properties of manganese ions (Mn2+), which cause a strong 
attenuation in the T1 spin-lattice relaxation time constant of water protons and thus produce 
positive contrast in areas where Mn2+ are accumulated when T1-weighted imaging is applied 
[377-379]. Furthermore, MEMRI utilises the fact that Mn2+ enter excitable cells through L-type 
voltage-gated Ca2+ channels [380, 381], as well as other Ca2+ transport routes, including the 
Na2+/ Ca2+ exchanger, the Na+/ Mg2+ antiporter, and the active Ca2+ uniporter in mitochondria 
[382, 383]. Upon entry into the cell, Mn2+ are sequestered in the endoplasmic reticulum and 
subsequently transported along axonal microtubules to the synaptic cleft, where they are 
released and taken up by the next neuron, traversing the post-synaptic membrane through 
voltage-gated Ca2+ channels [378, 384, 385].  
 
As a result of the above properties, Mn is an excellent contrast agent in translational 
neuroimaging rendering MEMRI a powerful, versatile tool for non-invasive in vivo imaging of 
brain cytoarchitecture and activity and for tracing axonal projections in studies of neuronal 
connectivity [386, 387]. Hence, MEMRI has been used for mapping the mature and developing 
brain in rodents and non-human primates [388-395], while activation-induced MEMRI (AIM-
MRI) has been applied in a number of studies as a technique for imaging activity in the brain 
[396-405]. In addition to the above, utilisation of Mn2+ as an in vivo neuronal tract tracer 
enables application of the MEMRI technique for imaging the visual, olfactory, auditory, and 
somatosensory pathways in a variety of species [384, 385, 406-415].   
 
For the purpose of such studies, aqueous solutions of MnCl2 are administered systemically or 
directly into the vicinity where the target neuronal population resides. After administration to 
neuronal somata, Mn2+ are transynapticaly relayed to the specific neuronal circuit via kinesin-
mediated anterograde transport mechanisms [416]. However, MEMRI may also exploit dynein-
mediated retrograde axonal transport of Mn2+ [416, 417]. Although the exact Mn2+ transport 
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mechanisms require further elucidation, it is established that Mn2+ movement within neurons is 
via active transport, rather than passive diffusion [407]. 
 
1.4.2. MEMRI of the visual pathway 
Given its neuroanatomical features, the central visual system constitutes an excellent model for 
MEMRI application. Mn2+ uptake by RGC is effected by ivit  MnCl2 injection. Upon entry into RGC 
somata, Mn2+ are anterogradely transported within RGC axon microtubules, transynapticaly 
relayed to tertiary neurons at the LGN, and subsequently to the primary visual cortex, thus 
enabling visualisation of the entire normal visual projection [407, 408, 413, 418-420].  
Importantly, MEMRI also enables longitudinal in vivo monitoring of damaged and regenerating 
RGC axons [406, 408, 421-423], as well as studies of comparative physiology between 
regenerating and non-regenerating species [424], and is thus a powerful tool for assessing the 
efficacy of therapeutic intervention strategies, including transplant-mediated repair, in 
experimental models.   
 
One of the main caveats in such investigations, however, is the risk of Mn2+-induced toxicity as 
a result of repeated/high doses of MnCl2 [425]. Thuen et al [407] demonstrated that ivit doses 
of 150-300nmol MnCl2 are safe, yield optimal RGC axon enhancement, while they may also have 
a neuroprotective effect on RGC neurons. Furthermore, Olsen et al [419] showed that RGC 
axon contrast enhancement is contingent on prolonged availability of ivit Mn2+ for uptake by 
RGC neurons, rather than high dosage of MnCl2. This suggested that manipulations, for 
example by use of biomaterials, which enable controlled release of ivit Mn2+ should achieve the 
dual purpose of optimising contrast enhancement and minimising the risk of Mn2+-induced 
cytotoxicity. Alternatively, fractionated doses of MnCl2 [426, 427] or dendritic manganese 
chelates [428] may be viable options, however, their utility in the visual system model remains 
to be tested.  Considering that MEMRI is unlikely to be used for monitoring axon regeneration in 
human patients receiving regenerative treatments, it is envisaged that the knowledge acquired 
from modifications of the MEMRI technique in the rat visual system, will enable the 
development of clinically applicable derivatives, which circumvent the issue of Mn2+-induced 
cytotoxicity.  
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1.4.3. Non-invasive in vivo imaging of cell transplants 
Of central importance in studies of transplant-mediated repair is the ability to verify the location 
of transplanted cells, resolve their integration with host tissues, and monitor their 
temporospatial migration non-invasively in vivo. An array of technologies is currently available 
for such investigations, including optical, acoustical, and nuclear imaging, as well as MRI [429, 
430]. Each method has advantages and disadvantages. For example, bioluminescence imaging 
enables in vivo tracking of transplanted cells and direct correlation between bioluminescent 
signal strength and number of live cells in the tissue, thus providing information about cell 
survival post-transplantation [429, 431, 432]. However, signal loss as a result of increasing 
tissue depth is a major limitation of the technique [429]. Cell graft rejection can also be imaged 
by ultrasound using, for example, phospholipid-based, perfluorobutane-filled microbubbles 
targeted to intracellular adhesion molecule-1 (ICAM-1), a marker for endothelial inflammatory 
cells, as demonstrated in a cardiac transplantation model [429, 433]. Nonetheless, this method 
does not allow quantification of transplanted cell death and is further limited by the fact that 
the ultrasound technique can only be applied to relatively small regions of interest, rather than 
for whole body imaging [429]. Nuclear imaging, including positron emission tomography (PET) 
and single-photon emission computed tomography (SPECT), allows imaging functional effects 
[434] and biodistribution of transplanted cells [429, 434-436]. While simultaneous detection of 
two probes for parallel assessment of cell graft function and host-tissue integration is possible 
using dual pinhole SPECT, the scope of this technique is confounded by the short temporal 
resolution of exogenous labels [429, 437, 438]. Moreover, potential radiotoxic, dilution, and 
leakage effects of radioligands on live tissues need to be thoroughly investigated [429]. 
 
1.4.4. Imaging cell transplants by MRI 
Due to its superior spatial resolution, MRI is one the most widely applied technologies for non-
invasive in vivo monitoring of transplanted cells. Visualisation of transplanted cells by MRI 
requires labelling of the cells with intracellular, or extracellular contrast agents. A variety of 
such agents are available including (i), bifunctional agents, such as gadolinium rhodamine 
dextran (GRID), which enable cell detection by MRI and identification in histological sections 
[439-441]; (ii), convertible contrast agents (based on MnO, MnO2, Mn3O4, and MnCO3), which 
switch from T2*-weighted contrast to T1-weighted contrast upon molecular dissolution inside 
lysosomes and endosomes [442]; and (iii), different types of metallic particles, including gold 
nanoparticles (Au3Cu1), aptamer-modified nanoparticles, and various types of functionalized 
derivatives, which enable  delivery of antibodies, ligands and drugs to target tissues [443-448].  
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 One of the most widely used classes of intracellular contrast agents comprises different types of 
ferumoxide-based microparticles/nanoparticles and their modified derivatives. These include 
poly(lactide-co-glycolide) (PLGA)-coated [449], poly(N,N-dimethylacrylamide) maghemite 
(PDMAAm)-coated [450], and D-Mannose-modified nanoparticles [451] with ferumoxide cores, 
superparamagnetic iron oxides (SPIO), ultra-small paramagnetic iron oxides (USPIO) [450-463], 
and micron-sized particles of iron oxide (MPIO) [464-466]. Although some of these contrast 
agents have been approved for clinical use, for example, Endorem™, Feridex® (SPIO), and 
Sinerem®, Combidex® (USPIO), intracellular uptake of these particles by means of endocytosis 
often requires long incubation times, while it also necessitates surface modification or 
conjugation with transfection agents [455].  Another consideration is that for single-cell 
detection by MRI, which may be desirable in transplantation studies that involve monitoring of 
the temporospatial migration of transplanted cells, very large numbers of SPIO/USPIO are 
required to achieve sufficient intracellular iron uptake for visualisation by MRI. This suggests 
that the application of these agents carries the inherent risk of intracellular iron overload, with 
associated cytotoxic effects and potential interference with the cells’ function and migratory 
capacity post-transplantation [467]. Some of these practical limitations can be overcome by 
using MPIO, which have a higher magnetite content than SPIO/USPIO and can thus achieve 
better iron loads using significantly less contrast agent [466, 467]. However, a major caveat in 
the use of intracellular magnetic labels is that imaging artefacts deriving from secondary uptake 
of the label by in situ macrophages cannot be excluded. As a consequence, correlation of MRI 
findings with those of histological/histochemical methods is imperative, as it adds interpretive 
acumen to the relevant investigations by evaluating the rigour of MRI data within an 
appropriate biological context.  
 
In addition to the above, the emergence of new classes of nonmetallic chemical exchange 
saturation transfer (CEST) agents has been met with great interest. The specific contrast agents 
applied alone, or in combination with ferumoxide agents, enable simultaneous imaging of 
multiple cellular and molecular targets [468-471] and are thus extremely important for non-
invasive monitoring of the effects and function of cell transplants in vivo. Finally, the evolution 
of other novel MRI-based methodologies, such as frequency-labelled exchange (FLEX) transfer 
[472], can be expected to be a driver for the development of sophisticated, versatile contrast 
agents which will elucidate dynamic changes in specific genes and proteins in response to cell 
transplants.  
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1.5. Biotechnology and nanotechnology in transplant-mediated repair 
1.5.1. Biomaterials
 
A pertinent issue in transplant-mediated CNS repair is optimisation of cell graft function and 
survival by mitigating the deleterious effects of host immune responses post-transplantation 
[473]. Equally important is the ability to direct the fate/differentiation of transplanted cells in 
situ, enhance their therapeutic potential, for example, by graft functionalisation and controlled 
expression of genes and proteins for targeted delivery in vivo, and to provide regenerating CNS 
axons with molecular and structural support to promote directional growth towards appropriate 
synaptic targets.  Such interventions are made feasible through advances in biomaterials 
science and nanotechnology, which allow manipulation of a multitude of natural and synthetic 
biomaterials for tailor-made applications in experimental models, as well as in regenerative 
medicine and tissue engineering. Examples include  microcapsules/microcarriers for 
immunoisolation and delivery of cells and genes to specific tissues [473-480], as well as  
biomimetic matrices with ECM properties, which act as biodegradable scaffolds for bridging CNS 
lesion cavities [473, 474] (Figure 1.7).  
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Figure 1.7 – Microcapsules and microcarriers can be utilised for cell transplantation. The semi-
permeable membrane of microcapsules protects encapsulated cells from immune responses in 
the host microenvironment. Microcapsules allow entry of O2 and nutrients into the capsule while 
they enable diffusion of therapeutic molecules and waste products out of the capsule. 
Microcarriers, on the other hand, support cell attachment to the surface of the capsule and can 
be utilised for scaffolding of CNS lesions. 
 
 
Although the choice of type and form of biomaterials is dictated by the specific aims of the 
therapeutic approach in each case, desirable properties include biocompatibility, mechanical 
stability, permeability, and ease of handling [476]. Representative examples of applications of 
different types of biomaterials in regenerative neuroscience models include (i), attachment of 
NSCs to modified PLGA particles and transplantation in stroke-induced cavities [481, 482]; (ii), 
transplantation of hydrogel matrices seeded with engineered fibroblasts to promote ON axon 
growth after intracranial ON lesion [483]; (iii), use of a self-assembling nanofibre peptide 
scaffold (SAPNS) to promote ON regeneration in chronic optic tract lesion [423]; (iv), use of 
poly(D,L)-lactide matrices for stem cell tissue engineering [484] and for co-transplantation of 
OECs and ONF to stimulate axon regeneration after spinal cord hemisection [293]; and (v), 
transplantation of mesenchymal stem cells seeded in modified hydrogel matrices to treat 
chronic spinal cord lesions [485]. 
27
1.5.2. Tailor-made alginate matrices 
 
Alginates are naturally occurring polysaccharides, comprised of unbranched copolymers of 1ĺ4 
linked ǃ-D-mannuronic acid (M) and Į-L-guluronic acid (G) [486, 487], which are found in algae 
[488] and certain types of bacteria [489, 490]. Alginates are promising candidate biopolymers 
for cell encapsulation as a result of their ionotropic properties [491] and the fact that they lend 
themselves to structural and compositional modification for tailored applications through the 
conversion of M-residues to G-residues with the use of C-5 epimerases [492-496]. The specific 
arrangement of G- and M- monomers in the polymer chains, and the type of divalent cation 
used for ionotropic gelation, such as Ca2+, Ba2+, and Sr2+ in the gelling solution, determine the 
strength, stability, syneresis, and permeability of the alginate microbeads and microcapsules 
[497-499]. In addition to the above, further modification of the alginates can be effected by 
engraftment of functional peptides, such as arginine-glycine-aspartic acid (RGD) [500]. Such 
manipulations aim to ascribe specific functional properties to the alginates by mimicking ECM 
conditions, which are expected to promote cell adhesion, survival, and differentiation post-
transplantation [500].  
 
The biocompatibility of different types of alginate hydrogels for immunoisolation of cell 
transplants has been studied with promising results [499-504]. Equally promising are specific 
applications of modified alginate matrices in neurotransplantation and CNS repair, including the 
use of alginate hydrogels for differentiation of neural stem cells [505-510], promotion of neurite 
outgrowth in vitro [511], as well as directed outgrowth of regenerating CNS axons in vivo 
[512]. Furthermore, the ability to modulate alginate hydrogel properties such as mechanical 
strength and stability suggests that alginates may have additional roles in CNS repair studies, 
such as utilisation for controlled release of MRI contrast agents for tracing of regenerating CNS 
axons in vivo. Clearly, the functional attributes of the alginates in each case should be 
determined by the type of CNS lesion, the specific reparative or imaging approach and, 
importantly, the type of cell(s) used to mediate repair. It is therefore imperative to thoroughly 
test and develop alginate matrices tailored to the specific requirements of individual 
intervention strategies. 
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2. Overview of methods 
 
This section describes the key methodology involved in the papers that comprise this thesis. A 
detailed description of the rest of the methods used is provided in the Materials and Methods 
section of each paper. 
 
 
Table 1. Overview of key methodology presented in this thesis 
  
  Method Paper
1. OEC purification and culture I, II, IV 
2. Intracellular labelling of OECs with MPIO I, II 
3. Optic nerve crush injury II 
4. Ivit and iON OEC engraftment II 
5. Ivit MnCl2 injections II 
   
6. In vivo and in vitro MRI   
6.1. T2*/T2-weighted imaging I, II  
6.2. 3D T1-weighted imaging II, II, III 
6.3. 2D T1-weighted imaging I, III 
   
7. Formation of Mn-alginate beads III 
8. RGD peptide coupling to alginates IV 
9. Epimerisation of alginates III, IV 
10. Cell encapsulation in alginates IV 
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 2.1. OEC purification and culture
 
The OECs utilised in this thesis were purified from neonatal Fischer rats as described by Barnett 
and Roskams [516]. Briefly, the olfactory bulbs of 4-5 P7/P8 rats were finely chopped, 
enzymatically digested in L-15 (Leibovitz) medium (Sigma), and triturated through a 26 gauge 
needle. Dissociated cells were incubated in a cocktail of the O4 (IgM at 1:4) and anti-
galactocerebroside (IgG3 at 1:2.) primary antibodies, followed by their fluorochrome 
conjugated class-specific secondary antibodies.  After rinsing, dissociated cells were incubated 
in goat anti-mouse IgM phycoerythrin and goat anti-mouse IgG3 fluorescein secondary 
antibodies (1:100, Southern Biotech). Fluorescence-activated cell sorting (FACS, Vantage 
Becton Dickenson) was used for OEC purification by selecting for galactocerebroside-negative 
and O4-positive cells. OECs were subsequently cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM GlutaMAX; Sigma) with 1.25% gentamicin (Sigma) and 5% FBS (Autogen Bioclear) on 
13g/ml poly-L-lysine- (PLL) (Sigma) coated cell culture flasks (Corning).  The cultures were 
supplemented with 500ng/ml fibroblast growth factor 2 (FGF2) (Peprotech, London, UK), 
50ng/ml heregulin (hrgǃ1) (R&D Systems Europe Ltd, Abingdon, UK), and 10-6 M forskolin 
(Sigma).  OECs were passaged at confluence. Purity of the OECs populations was assessed by 
p75NTR specific labelling and was always 98-100%. 
 
2.2. Intracellular labelling of OECs with MPIO 
 
MPIO with a diameter of 0.96m (Bangs Laboratories, US) were used for intracellular labelling 
of OECs. The specific MPIO are comprised of a COOH-modified styrene-divinyl benzene inert 
polymer with a  Fe3O4 magnetic core (27.8% w/w magnetite content) and a fluorescent label 
(Dragon Green; ex480, em520) (MC05F/8112; density 2.06g/cm3, 1% solids, 1.278x1010 
beads/ml; Bangs Laboratories, Inc, Fishers IN, US). After washing with PBS, the MPIO were 
resuspended in PBS or OEC media and added to the OEC cultures. Assessment of labelling 
efficiency was based on adjustment of the following parameters: (i), MPIO label concentration, 
expressed as number of MPIO particles per cell; minimum MPIO:OEC=10:1, maximum 
MPIO:OEC=100:1; (ii), degree of confluence of the OEC cultures, starting with 100% and 
reducing to 50%, (iii) duration of incubation, starting with 18h and reducing to 6h.  After 
labelling, the media were removed by aspiration and the cultures extensively washed with PBS, 
before addition of new media.  
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2.3. Optic nerve crush injury 
 
For ONC operations, inbred female Fischer rats (110-115g) were anaesthetised with 
subcutaneous injection of 0.4ml/100g of 2:3:3:4 mixture of Haldol/Midazolam/Fentanyl/sterile 
water respectively, under sedation with 4% isoflurane in 3% O2. ONC was performed according 
to Berry et al [143]. Briefly, after intraorbital exposure through a superior palperbal incision, the 
dural sheath of the ON was incised longitudinally and the ON crushed for 10s, 2mm caudal to 
the lamina cribrosa using microforceps (AgnTho’s AB, Lidingö, Sweden). Care was taken not to 
disturb the central retinal artery running inside the dural sheath along the ON.  Post-surgical 
analgesia was maintained with subcutaneous injections of 1.667l/g of 1:10 Buprenorphin 
(Tegmesic®, Schering-Plough, Brussels, Belgium) in sterile water.  Animals were kept in a 
12:12 artificial light-dark cycle and fed ad libitum.
 
2.4. Ivit and iON OEC engraftment 
 
For ivit OEC engraftment, a 3l suspension of 2.5x105 OECs was injected acutely post-ONC into 
the left eye of anaesthetised animals, immediately posterior to the ora serrata. The same 
suspension volume and OEC concentration were used for iON injections, 1mm proximal to the 
injury, i.e. between the lamina cribrosa and the ONC lesion site. A pulled-glass capillary 
micropipette with a tip diameter of ~0.1-0.2mm was used for the injections. To minimise reflux, 
the micropipette tip remained inside both the vitreous body (ivit groups), and the ON (iON 
groups), for a few seconds, before being slowly withdrawn.   
 
2.5. Ivit MnCl2 injections
An aqueous solution of 3ǋl of 150nmol MnCl2 was injected into the vitreous body of the left eye 
of anaesthetised animals, immediately posterior to the ora serrata, in the same manner as for 
ivit OEC engraftment above. 
 
2.6. In vivo and in vitro MRI
MRI was performed on a 7T Bruker Biospec Avance 70/20 (Bruker Biospin MRI, Ettlingen, 
Germany) small animal scanner. A 72mm volume resonator was used for RF transmission and 
an actively decoupled (i), mouse head surface coil (MPIO OEC phantom study), and (ii), rat 
head surface coil (in vivo experiments) for RF reception.  No surface coil was used for the in 
vitro experiments involving Mn-alginate beads. 
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 2.6.1. T2*/T2-weighted imaging 
For T2*-weighted imaging, a multi-gradient echo (MGE) sequence was used with the following 
parameters: TR=1000ms, TE=5, 10, 15, 20ms, flip angle 30%, FOV=2.8x2.5cm2, 
matrix=224x200, pixel resolution=125x125m2/pixel, number of slices=10, slice 
thickness=0.70mm (no gap), and an acquisition time of 16m40s with 5 averages. 
For T2-weighted imaging, a rapid acquisition with relaxation enhancement (RARE) spin echo 
sequence was applied with the following parameters: TR= 2000ms, TE=12, 36, 60ms, 
FOV=2.80x2.50cm2, matrix=224x200, pixel resolution 125x125m2/pixel, number of slices=20, 
slice thickness=0.70mm (no gap), and an acquisition time of 16m40s with 5 averages. 
 
2.6.2. 3D T1-weighted imaging 
 
For in vivo T1-weighted imaging, a 3D FLASH sequence was used with the following 
parameters: TR=12ms, TE=3.5ms, FOV=3.5x2.2cm3, acquisition matrix=224x192x141, voxel 
resolution 156x156x156 m/voxel; 12 averages were obtained and the acquisition time was 
33min 38s. 
 
To correct for the gradually reduced RF signal detected by the surface coil, two additional T1-
weighted 3D FLASH sequence scans were performed for in vivo MRI using coupled and single 
coil operations, respectively, with the same sequence parameters as in 2.5.3. above, but with 
reduced resolution and with an acquisition time of 2min 3s/scan.   
 
2.6.3. 2D T1-weighted imaging 
 
For imaging release of Mn2+ from alginate beads in vitro, the following sequence was applied:  
2D MSME evolution scanning: TE.=8.1ms, TR=500ms, FOV=30x40mm, matrix=128x64, slice 
thickness=1mm, NEX=1, 6 frames per h over 24h.  
2.7. Formation of Mn-alginate beads 
Five different alginate samples were used in the study of Mn2+/alginate beads: two 
commercially available alginates and three alginates of extreme composition: (i), High-G 
alginate from Laminaria hyperborea (67% G, intrinsic viscosity 620 ml/g) and (ii), high-M 
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alginate from Macrocystis pyrifera (40% G, intrinsic viscosity 820 ml/g) were obtained from FMC 
biopolymer and Sigma Chemicals, respectively. (iii), A polymannuronan alginate (polyM, 0% G, 
intrinsic viscosity 800 ml/g) was produced by an epimerase-negative mutant (AlgG-) of 
Pseudomonas fluorescens (28). (iv), A strictly alternating (polyMG) alginate (46% G, 0% GG, 
intrinsic viscosity 700 ml/g), and (v), a polyguluronan alginate (polyG, 88% G, intrinsic viscosity 
1150 ml/g) were produced by epimerising the bacterial polyM alginate with the C-5 epimerases 
AlgE4 and AlgE6, respectively. An electrostatic bead generator was used to form alginate beads 
by dripping a 1.8% (w/v) solution of Na-alginate (filtrated through 0.8 m filters, dissolved in 
ion free water) into gelling solutions containing divalent cations, i.e. (a),  0.1 M MnCl2 + 1 mM 
BaCl2, and (b), 0.1 M MnCl2 + 10 mM CaCl2.  
2.8. RGD peptide coupling to alginates
 
RGD peptide was coupled to alginates using carbodiimide chemistry. 3.5g-5g of purified 
mannuronan were dissolved in 1% phosphate buffer saline (PBS) solution overnight. EDC was 
added to the solution at 1:20 molar ratio to the uronic acid monomers of the alginate. Sulfo-
NHS was added as a co-reactant at a 1:20 molar ratio to the EDC and incubated for 2 hours 
(h). The peptide was then added at a concentration of 100mol/ml, as described by Rowley et 
al [500] and allowed to react for 20h before the alginate solution was purified through 
extensive dialysis against 3 shifts of 50mM NaCl, and against distilled water, until the water 
measured <2ǋs.  The alginates were subsequently freeze dried and stored at 4°C. 
2.9. Epimerisation of alginates 
Alginate consisting of G- and MG-blocks was made by epimerization using the C-5 epimerases 
AlgE4 (produced in Hansenula polymorpha) and AlgE6 (produced in Eschericia coli). To produce 
MG alternating alginate, AlgE4 enzyme was added to alginate at a 1:200 ratio in a mixture of 
0.25% (w/v) alginate, 50mM MOPS, 2.5mM CaCl2 and 10mM NaCl and incubated for 24h-48h at 
37ºC.  To produce alginates with a G-content of 50% and 70%, AlgE6 enzyme was added to 
MG alternating alginate at a ratio of 1:20 in a mixture of 0.25% alginate (w/v) and 50mM MOPS 
for 2.5h and 24h, respectively. To eliminate potential toxins, the epimerized alginates were 
purified through a carbon filter (PALL Corporation).   
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2.10. Cell encapsulation in alginates 
 
2% (w/v) alginate solutions were prepared from peptide alginates and control alginates by 
mixing with 0.3M D-mannitol (VWR) in sterile water. 2% alginate solution and OEC suspension 
were mixed in a 10ml syringe at a final concentration of 1.5x106 cells/ml in 1.8% alginate. 
Beads with encapsulated cells were formed by dripping the alginate solutions into a gelling bath 
containing 50mM CaCl2, 0.15M Mannitol and 10mM MOPS buffer in 1L sterile endotoxin-free 
water using an electrostatic bead generator with electrostatic potential difference 7kV, needle 
size of 0.35mm outer diameter, and flow at 10ml/h. Beads containing encapsulated 
OECs/myoblasts were transferred to 75cm2 cell culture flasks containing appropriate culture 
media and incubated at 37ºC with 7% (for OECs) and 5% CO2 (for myoblasts), respectively.  
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 3. Aims 
The aim of this project was to integrate MRI and biomaterials in the study of visual pathway 
repair mediated by olfactory ensheathing cell (OEC) transplants.   
 
Key objectives include: 
 
(i) Development of customised labelling protocols for efficient labelling of OECs with 
micron-sized particles of iron oxide (MPIO). 
(ii) Combining cellular MRI and manganese-enhanced MRI (MEMRI) for monitoring 
intravitreal (ivit) and intra-optic nerve (iON) OEC grafts and damaged/regenerating 
retinal ganglion cell (RGC) axons after visual pathway lesion. 
(iii) Testing the potential of ivit and iON OECs as mediators of visual pathway repair. 
(iv) Producing and testing modified alginates as systems for controlled release of Mn2+ 
for MEMRI 
(v) Producing and characterising arginine-glycine-aspartic acid (RGD)-peptide alginates 
and testing their interactions with OECs in vitro with a view to developing suitable 
matrices for future in vivo application. 
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4. Overview of papers
 
4.1. Paper I - Labelling of olfactory ensheathing cells (OECs) with micron-sized 
particles of iron oxide (MPIO) and detection by MRI  
The aim of this study was to test the suitability of MPIO, a widely applied class of T2* contrast 
agents, for intracellular labelling of OECs for detection by MRI in vitro and in vivo. We defined 
labelling efficiency in terms of (i), percentage of labelled OECs, and (ii), intracellular iron 
uptake, and proceeded to develop a tailored labelling protocol that can achieve both objectives 
without compromising OEC viability, proliferation, and migration capacity for application in 
future investigations of OEC-mediated repair after visual pathway lesion in rats monitored by 
MRI. 
 
We found that OECs avidly endocytose MPIO, achieving a labelling efficiency of >90% with 
incubation times as short as 6h, while the intracellular MPIO uptake was contingent on MPIO 
label concentration,  yielding intracellular iron loads between 1.90pg and 13.80pg. No adverse 
effects of the MPIO label in terms of cytotoxicity, altered cell morphology, proliferation and 
migration pattern in culture, were observed up to 96h post-labelling. Furthermore, MPIO-
labelled OECs were resolvable by MRI at 7T in vitro, and also in vivo, after engraftment in the 
vitreous body of adult rats.  
 
This study provides the first detailed protocol for safe, efficient labelling of OECs with MPIO for 
non-invasive imaging by MRI in conjunction with studies of CNS repair mediated by OEC 
transplants.  
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 4.2. Paper II - In vivo MRI of olfactory ensheathing cell grafts and regenerating 
axons in transplant-mediated repair of the adult rat optic nerve 
A key aim of this study was to combine cellular MRI and MEMRI to monitor OEC transplants and 
regenerating RGC axons in vivo, after visual pathway lesion in the adult rat, and to test whether 
MEMRI is sensitive enough to detect potential axon regenerative effects of OEC grafts.  
 
We found that the T1-weighted 3D FLASH sequence applied for MEMRI facilitates simultaneous 
visualisation of Mn2+-enhanced regenerating retinal ganglion cell (RGC) axons and MPIO-
labelled OEC grafts. Furthermore, the MEMRI technique was sensitive enough to detect axon 
regenerative responses to the iON grafts at 20dpl. However, the CNR profiles of animals with 
iON MPIO-labelled OEC transplants were partially distorted due to susceptibility effects of the 
MPIO proximal to the lesion. Ultrastructural analysis of tissue obtained at 40dpl revealed robust 
axonal sprouting and surviving iON OECs proximal to the lesion site. Importantly, formation of 
myelin of peripheral appearance proximal to the lesion site suggested a remyelinating role for 
iON OEC transplants. Finally, the ultrastructural study revealed secondary uptake of MPIO by 
macrophages and degradation of the MPIO label at >40dpl.   
 
The specific study demonstrated the applicability of MEMRI as a tool for monitoring repair of 
the rat visual pathway mediated by OEC transplants in terms of visualising MPIO-labelled OEC 
grafts and regenerating RGC axons, as well as detecting axon regenerative responses to OEC 
transplants. Being the first study to combine the application of two different contrast agents in 
the rat visual pathway lesion model, the study also revealed some of the methodological 
challenges involved in the specific MR imaging approach. Furthermore, the evidence of 
secondary uptake of the MPIO label by macrophages constitutes a reminder of the fact that 
relevant artefacts in such investigations cannot be excluded. Finally, the suggestion of a 
remyelinating role for iON OECs after ONC injury is a very promising finding, but in the absence 
of supplementary data to unequivocally confirm this observation, the specific result is regarded 
with cautious optimism.  
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4.3. Paper III - Mn-alginate gels as a system for controlled release of Mn2+ in 
manganese-enhanced MRI 
 
The aim of the study was to evaluate alginate beads of different composition in combination 
with different cross-linking divalent ions as systems for controlled release of Mn2+ in vitro and to 
provide proof of principle for potential application of such systems in vivo, by testing the utility 
of controlled release of Mn2+ from ivit Mn-alginate beads for MEMRI of the normal rat visual 
projection.  
 
We utilised different types of commercially available and modified alginates to form Mn-alginate 
beads and imaged the release of Mn2+ from the Mn-alginate beads in vitro, as well as in vivo, 
after unilateral ivit injection in rat, using a 7T MR scanner. Compartment model simulation and 
analysis found that the time constant (Ĳ1) that represents the rate of release of Mn2+ from the 
alginate beads greatly varied between the different types of alginates and had values between 
600min and 100min, corresponding to the order high-G  high-M > polyMG, as well as 
Ba2+>Ca2+. This means that reductions of ivit Mn2+ concentration up to 85% can be effected by 
selective adjustment of alginate composition and choice of cross-linking divalent ions.  
 
These findings are highly significant as they demonstrate the feasibility of designing and 
utilising alginate-based systems for controlled release of Mn2+, which enable optimal contrast 
enhancement and potentially circumvent the issue of Mn2+-induced toxicity. Furthermore, the 
pliability and versatility of alginates indicate that such systems can be used to adjust Mn2+ 
uptake, transport and clearance to the requirements of specific neuroanatomical and 
biophysical properties of the system under investigation, thus enabling the refinement of the 
MEMRI technique through the development of sophisticated derivative approaches. 
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4.4. Paper IV - Effects of RGD-peptide modified alginates on olfactory ensheathing 
cells and myoblasts 
The aims of the study were to produce RGD-peptide alginate capsules of different flexibility, 
characterise the modified alginates, test their effects on OECs in terms of cell survival, cell-cell, 
and cell-matrix interactions using both 3D and 2D cultures, and compare these interactions with 
those of myoblasts using the same culture substrates.  
 
Chemoenzymatic modification enabled RGD peptide coupling to the alginate by first introducing 
RGD peptide to mannuronan and subsequently introducing MG- and G-blocks using C-5 
epimerases, thus preventing interference with the G-blocks as a result of peptide coupling. 
Analysis using NMR spectroscopy determined the degree of RGD-peptide coupling, alginate 
composition, as well as downstream processes on the RGD-coupled alginates. 2D cultures of 
OECs and myoblasts revealed dynamic responses to the RGD-coupled alginates in terms of 
altered morphology and adhesion of the cells to the alginate substrate by extension of 
processes. Encapsulation in RGD-coupled alginates did not promote survival and/or 
differentiation of the cells.  
 
The present study demonstrates the utility of our protocol for alginate modification and 
characterisation, however it does not confirm improved OEC or myoblast survival in response to 
RGD-peptide modified alginates. While RGD-coupled alginates induced dynamic responses to 
OECs and myoblasts in terms of cell-cell, cell-matrix interactions, encapsulation in RGD-coupled 
alginates did not enhance survival/differentiation of either cell type in vitro. This suggests that 
further modification of the alginates is necessary, for example, by coupling more RGD peptide 
to the alginates, or by further modulating their composition. Clearly the ability to modify and 
thoroughly characterise the alginates is a major advantage in developing tailor-made matrices 
for transplantation of OECs and other cell types in different experimental models. 
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5. Discussion 
 
In the present study, we adopted an interdisciplinary approach in the investigation of 
transplant-mediated CNS repair, by (i), defining the biological context of the investigation in 
terms of experimental model and cell of interest, (ii), predicting potential outcomes of cell 
transplantation in the specific model, (iii), integrating MRI methodologies for monitoring cell 
transplants and regenerating CNS axons, and (iv), modifying biopolymers to address specific 
methodological and biological aspects of the study.  
5.1. Regeneration of RGC axons mediated by OEC transplants  
 
A key hypothesis in our study was that RGC axon regenerative effects can be mediated by 
transplantation of OECs after ONC injury. Initial assessment of the reparative effects of OEC 
transplants after ON lesion was based on analysis of MEMRI data at 20dpl. Intraorbital ON 
lesioning results in loss of 90% of RGC [344], while the spontaneous regenerative response of 
<10% of the remaining RGC is abortive and, thus, not sustained beyond 20dpl [344].  Based on 
previous studies by our group, in which the regenerative effects of LI and PNG after ONC in 
mouse and rat, respectively, were assessed by MEMRI [407, 418, 424], we predicted that RGC 
axon regeneration in response to ivit and iON OEC transplants, would be manifested as 
elevated CNR profiles along the ON proximal and, possibly, distal to the lesion site. The 
designations proximal and distal correspond to the ON segment from the lamina cribrosa up to 
the lesion site, and from the latter towards the chiasm, respectively.  
 
Based on the above assumptions, the observation at 20dpl that the CNR profiles of animals with 
ivit OECs were not significantly different (P>0.05; two-tailed t test) from those of untreated 
controls indicated that the ivit OEC grafts had no neuroprotective/regenerative effects. It can be 
argued that the lack of RGC axon response to the ivit OEC grafts may be attributed to poor 
graft function and/or survival, or insufficiency of the ivit transplants in terms of number of 
transplanted cells. However, a thorough investigation of the regenerative effects of ivit OECs 
after ONC injury was not implemented, as it did not constitute a primary goal within the 
framework of this study. In light of the above, it can only be concluded that potential 
neuroprotective/regenerative effects of ivit OECs on RGC may be marginal and, thus, not 
detectable by MEMRI [407].  
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Contrary to the above, analysis of the MEMRI data obtained from the iON groups, revealed 
differences (P0.05; two-tailed t test) between the CNR along the ON proximal, as well as 
distal to the ONC lesion site, compared to those of untreated controls, indicating a regenerative 
response to the iON transplants.  
 
These observations suggested that it would be interesting to investigate whether the axon 
regenerative effects detected by MEMRI in the iON transplanted animals would be sustained 
beyond 20dpl. However, given methodological considerations relating to potential toxic effects 
of repeated doses of MnCl2 on RGC neurons and OEC grafts (discussed in section 5.6), we 
decided that MEMRI should not be used beyond the 20dpl time point. Evaluation of the 
reparative potential of OECs at >40dpl, was thus based on ultrastructural analysis using TEM.   
 
Ultrastructural analysis at >40dpl revealed SLA proximal to the injury site in the iON 
transplanted animals, consistent with an axon regenerative response, thus confirming the 
MEMRI observations from 20dpl. Qualitative comparison with untreated controls showed that 
the degree of axonal sprouting observed in the iON transplanted group was far more extensive 
and, thus, consistent with axon regenerative effects of the iON OECs, rather than an abortive 
regenerative response triggered by the ONC injury.  Small numbers of SLA were also observed 
in the iON transplanted animals distal to the lesion site. Furthermore, we identified OECs 
extending long processes in close proximity with SLA and blood vessels proximal to the injury, 
providing indirect evidence of long-term survival and integration of OEC transplants with the 
host tissue. Thus, based on the observations at 20dpl and >40dpl, we conclude that there is an 
axon regenerative response to iON OECs in terms of increased axonal sprouting proximal, and 
to a far lesser extent, distal to the lesion site.  
 
Our findings partially confirm findings by Plant et al [346] and Liu et al [347] of axon 
regenerative responses to OEC transplants after rat visual pathway lesion.  Liu et al [347], 
however, reported long-distance RGC axon regeneration, and also functional recovery at 8wpl. 
This difference may be attributed to the fact that Liu et al [347] utilised human recombinant 
GDNF, in addition to OEC transplants. Although we recognize that combinatorial approaches 
may be better aligned towards promoting visual pathway repair, as they simultaneously address 
different factors involved in CNS recovery, our reparative strategy, on this occasion, was based 
on OEC transplants only. This is because one of the main aims of our study was to test the 
suitability of MEMRI as a method for monitoring OEC-mediated repair in the visual pathway. 
This implied that transplantation of OEC, unassisted by other factors, would allow investigation 
of the regenerative capacity of OECs per se and, by the same token, would provide a clearer 
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measure of MEMRI sensitivity in detecting the relevant responses. In addition to the above, our 
observation of surviving iON OECs at >40dpl contrasts with the findings by Plant et al [346] as 
these authors did not identify any surviving OECs in the ON at 7 weeks post-transplantation. 
However, differences in our corresponding experimental protocols may account for this 
discrepancy, including number of transplanted cells and time point for transplantation. In our 
study, 2.5x105 OECs were transplanted acutely after ONC lesion, compared to 5x104 cells 
transplanted at 5dpl in the study by Plant et al [346].   
 
Finally, additional methodological considerations require clarification. The OECs utilised in our 
study did not express GFP and would not have been readily identifiable in histological sections. 
This precluded correlation of MRI data with findings from ex vivo examination of tissue 
collected from OEC transplanted animals. Alternatively, immunohistochemistry could have been 
used, however, in the absence of a specific marker for OECs [264, 265], unequivocal 
identification is not possible. Furthermore, identification of OECs by immunoreactivity with 
p75NTR gives variable results and p75NTR expression is lost once the cells have differentiated into 
a myelinating phenotype, while Gap-43 immunoreactivity for detection of regenerating RGC 
axons was considered redundant in the presence of ultrastructural data.  
 
5.2. Can OECs play a remyelinating role in visual pathway repair? 
 
The ultrastructural study provided evidence of remyelination of ON axons by myelin of 
peripheral appearance, as indicated by its hue and lamellar periodicity [374]. This finding is 
promising, however, it should be interpreted with caution, given that remyelination by OECs is 
indistinguishable from that by Schwann cells [319-325]. In a previous study, Li et al [374] 
reported that remyelination of ON axons is mediated by iON Schwann cell transplants only, not 
by iON OECs. In our study, we utilised 98-100% pure OECs obtained exclusively from the OB, 
which precludes the presence of contaminating Schwann cells in the OEC transplant.  
Furthermore, we did not observe any new myelin formation in ON collected from untreated 
controls, while the observed myelin in the iON tissue was always apposed to OECs. Based on 
these observations, we may attribute the presence of new myelin to the transplanted OECs. 
However, the possibility that the observed myelin may be due to Schwann cells migrating from 
meningeal fibres, as a result of the ONC injury, cannot be excluded [327]. Immunostaining for 
P0 might have confirmed the type of myelinating cell. Such investigation, however, would be 
confounded by the absence of an unequivocal marker for OECs [264, 265] and the fact that the 
OECs used in this study did not express GFP.  Finally, a pertinent issue in this discussion is 
myelination by oligodendrocytes, given that the presence of iON OECs may either stimulate 
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myelin formation by endogenous oligodendrocytes, or impair it through a mechanism of 
competitive inhibition. Clearly, additional investigations are necessary to further explore and 
confirm a remyelinating role for OECs in visual pathway repair.  
5.3. To what extent can MPIO uptake by OECs be controlled?  
Labelling efficiency and cellular responses to intracellular labels can be expected to be 
contingent on the particular type of label and cell under investigation. A main consideration with 
regard to ferumoxide-based intracellular labels is the risk of cytotoxicity associated with 
intracellular iron overload [467]. It is therefore imperative to develop safe intracellular labelling 
protocols tailored to specific cell types and imaging requirements.   
 
Despite the fact that OECs are promising candidates in transplant-mediated repair, very few 
studies have utilised cellular MRI of OEC transplants [513, 514], thus little is known about the 
suitability of specific contrast agents for intracellular labelling of OECs for MRI.  In these earlier 
studies, the OECs were labelled using SPIO [513] and magnetodendrimers [514], while 
incubation time was 48h and 24h, respectively. Cell viability was assessed at one time point 
only, i.e. immediately after labelling, and no adverse effects of the label were reported, except 
for concentrations of SPIO of 6mg/ml, which were cytotoxic and resulted in complete loss of the 
OECs from the in vitro cultures [513]. Using the protocol developed in Paper 1, however, high 
labelling efficiency (>90%) was achieved with incubation times as short as 6h. Furthermore, cell 
proliferation, migration and survival were monitored over 96h post-transplantation, thus 
excluding potential delayed adverse effects of the intracellular label in vitro. No adverse effects 
of the intracellular MPIO label were observed at any time during the observation period. 
 
Labelling efficiency was defined as 90% MPIO-labelled OECs and a minimum intracellular iron 
load of 0.90pg, which allows single cell detection by MRI [442]. The definition of a minimum 
threshold for intracellular MPIO uptake for single cell detection by MRI was based on an earlier 
study by Shapiro and Koretsky [442]. For the purpose of future MRI studies, we wanted to 
ensure that our labelling protocol enables sufficient intracellular iron load to detect potential 
migration of individual or small numbers of OECs post-transplantation in vivo by MRI.  
 
We found that optimal labelling efficiency of >90% is achieved by incubation of 50% confluent 
OEC cultures with MPIO over a period of 6h. Individual OECs displayed differential intracellular 
MPIO uptake, while MPIO uptake was also contingent on the MPIO concentration used for 
labelling and was in the range of 12-115 endocytosed MPIO. This corresponds to 1.90-13.80pg 
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of intracellular iron load, which is considered sufficient for single-cell detection by MRI at a 
resolution of 100m, based on previous findings [442]. Monitoring of the MPIO-labelled OECs 
over a period of 96h post-labelling and comparison with unlabelled control OECs did not reveal 
any differences in cell survival, proliferation, and migration capacity in vitro, showing no 
adverse effects of the MPIO label.  
 
The observation of differential uptake of the MPIO label by individual OECs, irrespective of 
MPIO label concentration and length of incubation is hardly surprising, given that intracellular 
MPIO uptake by individual cells cannot be fully controlled under experimental conditions. At the 
same time, the specific finding confirms the assumption that partial control of intracellular iron 
load can be effected by using smaller-diameter MPIO with lower magnetite content, and shorter 
incubation times, thus limiting the risk of cytotoxicity associated with intracellular iron overload.   
Another important consideration is MPIO label retention after endocytosis. In our study, the 
MPIO were retained by the OECs throughout the incubation period. Interestingly, however, the 
specific MPIO type and labelling protocol developed in our study were utilised by a different 
research group for intracellular labelling of myeloma cells. After initial uptake of the MPIO label, 
these investigators found that the MPIO were rejected by the myeloma cells n vitro , possibly 
via an efflux mechanism (Dr Therese Standal; personal communication). Although this response 
may be explained by specific biochemical properties pertaining to cancer cells, the particular 
observation further emphasises the importance of thoroughly testing the suitability of different 
intracellular labels and protocols for specific cell types. Intracellular MPIO retention by specific 
cell types may be another factor that cannot be fully controlled under experimental conditions. 
In such cases, potential rejection of the MPIO label by transplanted cells post-transplantation in 
situ would seriously impact the usefulness of relevant MRI data.   
5.4. Viability and function of MPIO-labelled OECs in vivo  
 
The protocol developed in Paper 1 ensured that labelling of OECs with MPIO does not 
compromise cell viability, proliferation, and migration capacity in vitro, as demonstrated in a 
series of assays performed up to 4d post-labelling. While these results confirm the safety and 
efficiency of MPIO-labelling for the purposes of the MRI protocols used in Paper 2, they do not 
constitute undisputable predictors of MPIO-labelled OEC behaviour post-transplantation in vivo. 
Considering the framework of our study, a discussion on in vivo function and survival of 
transplanted MPIO-labelled OECs, can only be based on indirect measures. 
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As discussed earlier, MEMRI did not detect any RGC axon responses to ivit OEC transplants. If 
we were to assume that this lack of regenerative response can be attributed to poor OEC 
survival and/or function post-transplantation, MPIO-labelling per se does not appear to be a 
contributing factor.  This is because equivalent observations were made in the animal groups 
with ivit unlabelled OEC, i.e. both MPIO-labelled and unlabelled ivit OEC groups had CNR 
profiles that were not significantly different from those of untreated controls (i.e. P>0.05; 
paired t test).   
 
On the other hand, MEMRI detected axon regenerative responses to both MPIO-labelled and 
unlabelled iON OECs, providing indirect evidence of MPIO-labelled OEC function post-
transplantation. On this occasion, the CNR profiles of animals with unlabelled iON OECs were 
significantly higher than those of untreated controls (P=0.02; paired t test). The differences in 
the CNR of MPIO-labelled iON OEC and untreated control animals were marginally significant 
(P=0.05; paired t test). It can be argued that this may be an indicator of reduced survival 
and/or efficacy of the iON MPIO-labelled OEC graft as a result of intracellular MPIO. However, 
the lower CNR profiles observed in the MPIO-labelled OEC group can be explained by distortion 
of the CNR of the Mn2+-enhanced ON as a result of T2* effects from MPIO proximal to the 
lesion site (please see section 5.5), rather than impaired iON graft function and/or survival as a 
result of MPIO labelling.  
 
Finally, ultrastructural analysis identified MPIO-labelled OECs extending long processes in close 
apposition with SLA and blood vessels, thus providing evidence of long-term survival, function 
and integration of iON MPIO-labelled OEC grafts with host tissue. Although the above 
observations suggest that intracellular MPIO may not compromise the viability and function of 
MPIO-labelled OEC grafts in vivo, potential adverse effects of intracellular MPIO post-
transplantation should be thoroughly investigated in a different study, designed specifically for 
this purpose. 
 
5.5. Monitoring MPIO-labelled OEC transplants by MRI. Fact or artefact?  
 
Cellular MRI provides information about cell graft localisation immediately post-transplantation, 
while it also enables longitudinal monitoring of transplanted cell movements and survival in situ, 
albeit with certain caveats. 
 
MPIO-labelled OECs can be imaged both with T2*- and T2-weighted MRI. T2*-weighted gradient 
echo sequences are highly sensitive to the MPIO label. However, consistent with our 
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expectations, better image quality was achieved with T2 imaging. In the pilot experiment 
described in Paper 1, the T2*-weighted sequence revealed a large hypointense region in the 
ipsilateral eye of ivit transplanted animals consistent with ivit MPIO-labelled OECs. No 
hypointense region was present in the contralateral eye, in which unlabelled OECs had been 
transplanted.  Similarly, in Paper 2, the ivit MPIO-labelled OEC graft was unequivocally detected 
with T2*-weighted imaging, while no hypointense region was revealed in the contralateral eye 
of the animals after saline injections.  
 
Unequivocal detection of the iON MPIO-labelled OEC transplants based on T2*-weighted images 
alone was confounded by the fact that potential blood/air artefacts in the region of the injury 
could not be excluded. Nonetheless, analysis of SNR comparing the ipsilateral and contralateral 
ON of iON engrafted animals and untreated controls revealed signal attenuation proximal to the 
injury side consistent with the MPIO-labelled OEC graft.  
 
An important finding in our study is the evidence of secondary MPIO uptake by macrophages 
revealed by the ultrastructural study. This observation was not entirely unexpected. It 
reiterated, however, one of the main limitations associated with the use of intracellular contrast 
agents such as MPIO, i.e. imaging artefacts derived from secondary uptake of the label by in 
situ macrophages and other scavenger cells. Furthermore, the evidence of MPIO degradation 
revealed by the ultrastructural study questions the suitability of the MPIO label for longitudinal 
studies beyond 40dpl. Apart from false positives derived from secondary MPIO uptake, potential 
degradation of the label within transplanted cells might significantly compromise the efficacy of 
cellular MRI, resulting in signal loss/ dilution, while it may also have deleterious effects on long-
term graft function and survival.  
 
Additionally, although tracking of cell movements by MRI may be desirable, in vivo monitoring 
of potential migration of the ivit and iON transplanted MPIO-labelled OECs by MRI was not 
possible in our study. Although individual cells had enough intracellular MPIO for single cell 
detection by MRI, the large susceptibility effects induced by the intracellular MPIO label limited 
resolution to the macroscopic graft. 
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5.6. MEMRI in combination with T2* contrast agents – imaging, interpretation, and 
toxicity 
 
In the present study, MEMRI was applied for in vivo monitoring of RGC axons after visual 
pathway lesion and transplantation with OECs. Consistent with previous findings, MEMRI 
enabled visualisation of damaged and regenerating RGC axons 24h after ivit injection of 
150nmol of MnCl2, demonstrating the efficacy of the technique for CNS axon tracing in vivo 
[406-408, 418-419, 424]. Analysis of the MEMRI data using a semi-automatic segmentation 
technique [418] provided the CNR profiles of the Mn2+-enhanced ON in the different 
experimental groups.   
 
As discussed earlier, based on previous studies [408, 421-424], we predicted that potential 
axon regenerative effects of OEC transplants would be reflected in increased CNR proximal and, 
possibly, distal to the lesion site.  Furthermore, previous work by our group [407] determined 
that the lowest axon density resolvable by MEMRI is 125 000 axons/mm2 and that anterograde 
transport of Mn2+ in RGC axons is via kinesin-mediated anterograde transport mechanisms, thus 
requiring viable axons [419]. As discussed in section 5.1, the fact that no significant differences 
were found in the CNR of the ivit engrafted groups compared to untreated controls at 20dpl, 
suggested that the ivit OEC transplants did not have a neuroprotective/regenerative effect on 
RGC neurons. Contrary to this finding, analysis of the CNR profiles along the ON of animals with 
iON MPIO-labelled OEC transplants compared to untreated controls, revealed marginally 
significant differences at 1-3mm from the lamina cribrosa, indicative of an axon regenerative 
response to the graft. However, the CNR profile of the Mn2+-enhanced ON of iON MPIO-labelled 
OEC animals was distorted by susceptibility effects induced by the presence of MPIO proximal 
to the lesion site. Comparison of the CNR profiles of the iON unlabelled OEC group with 
untreated controls, revealed statistically significant differences at 0.6mm-2mm (P=0.02; paired 
t test) from the lamina cribrosa, consistent with an axon regenerative response to the iON OEC 
transplant.  
 
Notwithstanding the distortion of the CNR profiles of the Mn2+-enhanced ON as a result of the 
iON MPIO, the MEMRI technique was sensitive enough to detect axon regenerative responses 
to MPIO-labelled OEC transplants. On the other hand, the challenges in the interpretation of 
MEMRI data indicate that combination of different contrast agents in future studies may require 
the development of sophisticated post-processing tools that can compensate for the loss of T1 
signal as a result of susceptibility effects derived from T2* contrast agents. Furthermore, spin 
echo sequences, such as RARE, are less sensitive to T2* effects than gradient echo sequences, 
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such as FLASH. However, gradient echo sequences are faster and yield higher SNR, thus 
enabling better resolution and significantly reducing scanning times. These factors were taken 
into account in applying gradient echo sequences for the purposes of the specific study. 
 
An important result in our study was that the T1-weighted 3D FLASH sequence applied for 
MEMRI of RGC axons, simultaneously detected the MPIO-labelled ivit and iON OEC transplants. 
This finding can be explained by the fact that T2* susceptibility effects derived from the MPIO 
destroy the Mn2+-derived T1 signal. Although simultaneous detection of MPIO-labelled grafts by 
MEMRI was not a primary goal of our investigation, the specific effect may be useful in terms of 
reducing scanning times for each animal in similar experimental protocols.  On the other hand, 
the interplay between the two contrast agents poses certain methodological challenges.  
 
A main consideration in the above study was that serial in vivo imaging of RGC axons using 
MEMRI would necessitate co-localisation of MnCl2 with ivit and iON labelled OEC grafts at 
specific time points. Although the ivit dose of 150nmol of MnCl2 used in the study does not 
induce toxicity, while it has also been reported to have a neuroprotective effect on RGC neurons 
[407], potential toxic effects of repeated ivit doses of MnCl2 on OEC transplants and RGC 
neurons could not be excluded. Another consideration was that Mn2+-induced toxicity might be 
exacerbated in the presence of intracellular iron from the MPIO label, and vice versa. We 
therefore decided to postpone MEMRI until 20dpl so as not to interfere with OEC graft function 
and survival by introducing MnCl2 to the tissue acutely post-transplantation. The same 
considerations indicated that MEMRI beyond the 20dpl time point should not be used in the 
specific experimental protocol. As a result, ultrastructural analysis rather than MEMRI was used 
for follow up of the animals at >40dpl.  
 
Taken together, the above findings illustrated some of the opportunities and challenges 
involved in integrating MEMRI as a tool for monitoring transplant-mediated repair after visual 
pathway lesion. While the technique indeed enabled detection of axon regenerative responses 
to the iON OEC transplants, correlation of the MEMRI data with ultrastructural findings was 
essential for correct interpretation and/or verification of the MEMRI observations. Furthermore, 
the risk of cytotoxic effects as a result of co-localisation of Mn2+ and OEC transplants, as well as 
interplay between T1 and T2/ T2* contrast agents, are factors that must be taken into 
consideration in future studies involving serial in vivo MEMRI of RGC axons after transplantation 
of MPIO-labelled OECs.  
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5.7. Controlled release of Mn2+ from alginate beads - what can it achieve?  
A novel approach in our study was the development of tailor-made alginates for controlled 
release of Mn2+ for future MEMRI applications in studies of CNS damage and repair.  The 
rationale behind this approach was that such systems should enable optimal contrast 
enhancement in MEMRI and also minimise the inherent risk of Mn2+-induced toxicity associated 
with repeated and/or high doses of Mn2+. This rationale was based on earlier observations 
regarding Mn2+ uptake into neurons [419], as well as differential structural, mechanical, and 
functional properties of modified alginate gels in physiological conditions [492-494, 497, 498, 
515]. 
 
Earlier findings suggested that there is a plateau of maximum Mn2+ entry into neurons [419], a 
corollary of which being that increased Mn2+-induced signal enhancement is contingent on 
prolonged Mn2+ availability, rather than on Mn2+ dose.  This indicated that regulation and 
adjustment of Mn2+ release to the neuronal uptake threshold can be expected to dramatically 
reduce exposure of neurons to Mn2+. 
 
Furthermore, previous studies demonstrated that the compositional and structural properties of 
alginate can be modulated by conversion of M-residues to G-residues using mannuronan C-5 
epimerases [492, 493, 494, 497]. Additionally, it is known that alginates display different 
affinities to divalent ions such as Ba2+ and Ca2+ [498] and that the binding between guluronic 
acid residues and Ca2+ or Ba2+ is characterised by strong and specific auto-cooperativity [515]. 
In physiological conditions, alginate hydrogels have a tendency to swell and dissolve, as 
divalent crosslinking ions are released in competition with non-gelling ions, with each 
crosslinking ion being replaced by two Na+. However, more stable gels can be produced using 
high G-content alginates, or divalent ions, such as Ba2+, which have a high affinity to alginate. 
At the same time, given that the affinities of Ba2+, Ca2+, and Mn2+ to alginate are in the order 
Ba2+>Ca2+>>Mn2+, we predicted that formation of alginate gels using gelling solutions 
containing (i), BaCl2 and MnCl2, and (ii), CaCl2 and MnCl2, will result in differential rates of 
release of Mn2+ under physiological conditions.  
 
Consistent with our predictions, elemental analysis and stability studies revealed distinct 
differences in the ion binding capacity of the different Mn-alginate gels. As expected, Mn/Ba-
alginate gels were most stable. Analysis of the MRI data and simulation of the ivit Mn2+ release 
and concentration in the beads and in the vitreous using a compartment model confirmed the 
above findings. Two time constants for ivit Mn2+ release were extracted from the model, i.e. a 
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long and a short time constant (Ĳ1 and Ĳ2, respectively), corresponding to slow and fast rates of 
release. While the short time constant hardly varied between the different alginates, there were 
significant differences in the long time constant (i.e. 600min-100min) in the order high-G  
high-M > polyMG, as well as Ba2+>Ca2+, i.e. contingent on the crosslinking ions.  
 
Unilateral ivit injection of Mn-alginate beads resulted in clear enhancement of the rat visual 
projection consistent with uptake of Mn2+ released from the beads by RGC neurons and active 
anterograde transport within RGC axons [416-417]. Simulation of the ivit Mn2+concentration 
showed that controlled release of Mn2+ from alginate with a time constant of 600min, 
representing the rate of Mn2+ release, effectively reduced maximum ivit Mn2+ concentration to 
57%, 21%, and 15%. This relates to an initial amount of bound Mn2+ stipulated at 20%, 80%, 
and 100%, respectively. On the other hand, a time constant of 100min, led to a corresponding 
reduction of ivit Mn2+ to 63%, 46%, and 44%. Furthermore, we predict that the use of Mn-
alginates for controlled release of Mn2+ can achieve reduction of maximum ivit Mn2+ 
concentration by ~85%. Considering that a bolus injection results in ivit Mn2+ concentration of 
100%, the large reductions in the ivit Mn2+ concentration facilitated by controlled release of 
Mn2+ from tailor-made alginates are highly significant in terms of reducing the risk of Mn2+ 
toxicity to RGC axons.  
 
In light of the above, we provide proof of principle for the design of alginate-based systems for 
controlled release of Mn2+ for MEMRI. We propose that such systems can be customised for use 
with specific experimental models, taking into account the particular bioanatomical/biophysical 
properties of the neuronal populations under investigation in terms of Mn2+ uptake, transport 
and clearance. Such applications can be expected to enhance the versatility and scope of the 
MEMRI technique for safe application in longitudinal studies of CNS damage and repair.  
 
5.8. Modification of alginates with RGD-peptides – developing an ideal matrix? 
 
One of the main considerations in studies of transplant-mediated repair is cell graft rejection as 
a result of immune responses. Although this type of host response may be modulated by the 
use of immunosuppressive treatments, or circumvented by utilising autologously derived or 
syngeneic transplants, it is often the case that the function, survival and integration of the 
transplanted cells with the host tissue is poor. With regard to OECs, survival post-
transplantation can be expected to be as low as 50% [248]. Furthermore, our observations in 
Paper 2 indicated that a possible reason for the lack of neuroprotective/regenerative effects of 
ivit OEC transplants may have been poor function and/or survival of the OEC graft post-
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transplantation in the vitreous.  This suggested that enhanced benefits of transplanted OEC 
might be derived through utilisation of biopolymer matrices for cell encapsulation.  
 
Based on the knowledge that the structural and mechanical propertied of alginates lend 
themselves to substantial modification [492, 493, 494, 497] and that RGD-peptide coupling to 
alginates promotes differentiation, adhesion, and survival of encapsulated cells by mimicking 
ECM conditions [500], we proposed to test the effects of RGD-peptide modified alginates as 
substrates for the culture of OECs in vitro with a view to future applications in connection with 
in vivo transplantation studies. Given that the interactions between RGD-alginates and 
myoblasts are well-characterised [500, 517], we used myoblasts as a reference cell line in the 
study.  
 
The strategy for alginate modification adopted in our study involved introduction of bioactive 
ligands to the M-residues of the alginate using a chemoenzymatic approach. G-residues were 
subsequently introduced to the alginate by epimerisation with mannuronan C-5 epimerases (as 
in Paper 3). The particular approach ensured that there is no interference with G-blocks as a 
result of the peptide coupling, thus allowing the G-blocks to be the main contributor to the 
formation of the gels.  
 
Another advantage in our methodological approach is that the proportions of M- and G- 
sequences and grafted functional peptide in our modified alginates, as well as downstream 
effects, were determined by NMR spectroscopy, while molecular weight characterisation was 
achieved by intrinsic viscosity measurements. This type of characterisation is very important 
given that the structural and compositional properties of the modified alginates may thus be 
correlated with observations from in vitro assay studies to elicit specific interactions with the 
cells under investigation, also with a view to in vivo applications.  
 
Characterisation of the alginates showed that modification of the alginates’ composition by 
epimerisation was consistent with previous findings [492, 493, 494, 497]. Utilisation of the 
RGD-coupled alginates and their non-coupled equivalents as substrates for OEC and myoblast 
culture in the form of flat gels (2D cultures) revealed dynamic responses to the RGD-coupled 
alginates in terms of altered OEC and myoblast morphology, formation of large clusters 
scattered across the surface of the gels, and adhesion of the cells to the alginate substrate by 
extension of bipolar processes. The specific morphological phenotype is largely unseen for OECs 
[256], while it denotes an intracellular response in terms of gene/protein expression affecting 
the cytoskeletal structure. On the other hand, encapsulation in RGD-coupled alginates did not 
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promote survival and/or differentiation of OECs and myoblasts in vitro. It is postulated, 
however, that further modification of the alginates, for example by coupling more functional 
peptide, or decreasing the G-content of the alginates may be necessary. 
 
The above findings are interesting with regard to future applications of RGD-peptide alginates in 
experimental studies of CNS repair mediated by OEC transplants. They indicate that 
introduction of RGD-peptide to the alginates may have an epigenetic effect on OECs, elucidation 
of which may lead to the development of tailor-made, functionalised alginate matrices for 
encapsulation of OECs with a view to promoting OEC survival and specific cell functions, such as 
increased secretion of neurotrophic factors.  Furthermore, it can be envisaged that modification 
of alginate matrices with functional peptides can by used to produce scaffolds which promote 
enhanced function and survival of seeded OECs, alone or in combination with other cell types. 
Such scaffolds may also provide molecular guidance and structural support to regenerating 
axons, facilitating directional growth towards correct synaptic targets distant to the lesion site.  
 
53
  
 
 
54
 6. Conclusions 
 
The aim of this thesis was to integrate MRI and biomaterials in the study of visual pathway 
repair mediated by OEC transplants.  Based on the findings of the relevant investigations, we 
can draw the following main conclusions: 
 
(i) MRI enables simultaneous in vivo monitoring of OEC transplants and regenerating 
RGC axons, however, signal distortions as a result of interplay between T1 and T2* 
contrast agents, as well as false positives in terms of imaging artefacts derived 
from secondary uptake of intracellular T2* contrast agents in situ, necessitate 
careful correlation of the MRI data with ultrastructural findings for correct 
interpretation and/or verification of MRI-based observations.  
(ii) OEC transplants have an axon regenerative effect and, possibly, a remyelinating 
role after iON transplantation following ONC injury. 
(iii) Tailor-made Mn-alginate beads can be utilised for controlled release of Mn2+ as a 
means of optimising contrast enhancement and minimising the risk of Mn2+-induced 
cytotoxicity, thus providing a significant refinement of the MEMRI technique. 
(iv) RGD-modified alginates induce dynamic responses on OECs in terms of 
morphology, cell-cell, and cell-matrix interactions, suggesting that further 
modification of the alginates may produce tailor-made, functionalised alginate 
matrices with ECM properties to be used for OEC encapsulation/seeding in models 
of CNS repair mediated by OEC transplants.  
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7. Future directions 
 
Integration of imaging, biomaterials, and nanotechnologies is important in investigations of CNS 
damage and repair. However, although advances in these technologies create opportunities for 
innovation and thus enable investigations in neuroscience which might have been inconceivable 
only some decades ago, their application should be hypothesis-driven rather than technology-
driven. In other words, technology alone, no matter how powerful, may not be expected to 
elucidate key mechanisms of CNS damage and repair unless it is supported by rigorous 
biological principles and ability to address specific biological questions. 
 
The complexity of the mechanisms of CNS damage and repair suggests that multi-factorial 
approaches may be better-aligned towards promoting repair of the damaged CNS after injury. 
Future research may thus benefit from the utilisation of biomaterials and nanotechnologies to 
optimise the effects of cell transplants in situ, deliver genes and proteins to appropriate targets, 
modulate the inhibitory nature of the lesion microenvironment, and promote axonal 
regeneration and re-establishment of lost synaptic contacts. Furthermore, emerging 
technologies such as bioprinting may be important for producing customised functional matrices 
for scaffolding of different types of CNS lesions. 
 
Ability to monitor and elucidate the efficacy of transplant-mediated CNS repair in vivo, can be 
expected to rely on multimodal imaging and to integrate different MRI technologies, such as cell 
tracking, MEMRI, fMRI, and DTI/tractography, with MR spectroscopy and PET, to evaluate 
different aspects of the reparative process. Smart contrast agents, which circumvent the 
vagaries of imaging artefacts and which enable visualisation of genes and proteins post-
transplantation are also of great interest. However, appropriate correlation of in vivo imaging 
data with the findings of more traditional methods, such as EM, immunohistochemistry and in 
situ hybridisation, may still be necessary for rigorous evaluation of the efficacy of therapeutic 
interventions in experimental CNS lesion models.  
 
Finally, successful integration of interdisciplinary approaches in regenerative medicine may, in 
the future, contribute towards resolving the lack of regenerative capacity in the CNS.  
 
In the words of Ramón y Cajal: ‘It is for the science of the future to change, if possible, this 
harsh decree. Inspired with high ideals, it must work to impede or moderate the gradual decay 
of neurons, to overcome the almost invincible rigidity of their connections, and to re-establish 
normal nerve paths, when disease has severed centres that were intimately associated’. 
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Abstract
One of the main challenges in tissue engineering and regenerative medicine is the ability to 
maintain optimal cell function and survival post-transplantation and to protect the transplanted 
cells from immune responses and rejection in the host-tissue microenvironment. Biomaterials 
such as alginates can be utilised for immunoisolation, while they may also provide structural 
support to the cell transplants by mimicking the extracellular matrix. In the present study, we 
produced RGD-peptide coupled, stable alginates of variable flexibility by adopting a unique 
strategy for controlling the peptide coupling and G-content of the alginates. We characterised 
the alginates and proceeded to test their interactions with olfactory ensheathing cells (OECs) 
and myoblasts in 2D and 3D cultures.  We found that RGD-peptide modified alginates induced 
distinct cell-substrate interactions, demonstrated as marked morphological changes in 2D 
cultures of OECs and myoblasts, and partially enhanced survival, compared to unmodified and 
control alginates. 3D cultures, however, did not demonstrate substantial benefits of RGD-
modification in terms of improved encapsulated cell viability. Taken together, our findings 
suggest that further modification, for example, by coupling more RGD peptide to the alginate 
and/or reducing the rigidity of the 3D network, might be necessary in order to significantly 
enhance the survival of encapsulated OECs and myoblasts, with a view to future transplantation 
studies.  
1. Introduction 
In the last decades, cell therapy has emerged as a promising approach in translational 
medicine, with potential applications in the treatment of a multitude of conditions, ranging from 
diabetes (1-5), and bone defects (6), to cancer (7), and central nervous system (CNS) lesions 
as a result of trauma [8-10] or neurodegenerative disease (11-13).  Contingent on cell type and 
disease/injury under treatment, cell transplantation may aim to replace and/or regenerate 
damaged tissues, promote de novo tissue formation, or deliver secreted factors and therapeutic 
molecules in situ (14, 15).  The success of cell therapy, however, is often confounded by poor 
cell function, survival, and integration with host tissue post-transplantation, as well as by the 
need for immunosuppression in experimental and clinical protocols which involve the use of 
allografts or xenografts (16). To circumvent some of these issues, biomaterials are increasingly 
used in tissue engineering and regenerative medicine as they may provide the dual benefits of 
immunoisolation and structural support to encapsulated cells, mimicking extracellular matrix 
(ECM) conditions for enhanced cell-cell and cell-tissue interactions (17,18). Such matrices may 
also enable controlled cell proliferation, fate and differentiation in situ (17, 18).  
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 Alginates, a generic term for naturally occurring polysaccharides found in algae (19) and some 
bacteria (20, 21), are widely used for microencapsulation of a variety of cell types (22-27). 
Alginates are linear unbranched copolymers of 1ĺ4 linked ǃ-D-mannuronic acid (M) and Į-L-
guluronic acid (G) and their superior ionotropic properties (28) and biocompatibility render them 
particularly suitable for formation of hydrogel beads for cell encapsulation. Furthermore, 
alginates can be structurally and compositionally modified by converting M-residues to G-
residues using mannuronan C-5 epimerases, while they can also be grafted with functional 
peptides such as arginine-glycine-aspartic acid (RGD), to enhance cell adhesion (29). Such 
manipulations enable tailoring and optimisation of the alginates to meet specific requirements 
for mechanical stability and functionality (30-35).   
 
In the present study, we aimed to (i), produce peptide-coupled, stable alginate microbeads of 
variable flexibility by adopting a unique strategy for controlling the degree of peptide grafting as 
well as the G-content of the alginates, and (ii), characterise the modified alginates and monitor 
and compare their interactions with two different cell types, both in 3D and 2D cultures. We 
used a chemoenzymatic strategy (32, 36) to introduce bioactive ligands exclusively to the M-
residues of alginate in a two-step process. First, a pure mannuronan was grafted with RGD 
peptides using carbodiimide chemistry, and then, it was treated with mannuronan C-5 
epimerases, which convert non-substituted M-residues into G-residues in the alginate chain (32-
34). We determined the proportions of M- and G- sequences and the degree of peptide 
substitution in the modified alginates using NMR spectroscopy, and further characterised the 
molecular size of the grafted alginates by intrinsic viscosity measurements. The alginates were 
purified by active coal filtration. We proceeded to test whether the modified alginates, in the 
form of flat gels (2D culture) and microbeads (3D culture), enhance cell survival and/or 
differentiation and whether they thereby render themselves as suitable substrates for 
immobilisation of olfactory ensheathing cells (OECs), a promising candidate cell type in 
transplant-mediated CNS repair (37), with a view to future in vivo transplantation studies in 
experimental CNS lesion models. C2C12 myoblasts, a well-characterised cell line in 
immobilisation studies utilising RGD-coupled alginates (29), were used as a reference cell line in 
the study.   
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2. Materials and Methods 
2.1. Alginate 
Mannuronan isolated from an epimerase-negative mutant (ALG-) of Pseudomonas fluorescens 
(batch 512-215-01 TP, FM=1, [ǆ]=1614ml/g) was modified by coupling a hexapeptide with the 
sequence GRGDSP to the C-5 carboxyl group of mannuronic acid monomers. UPLVG (batch 
FP603-04, NovaMatrix™, Norway) was used as control alginate. 
 
2.2. Peptide coupling 
Two batches of alginates, i.e. batch 1, and 2, were produced by peptide coupling of sequences 
GRGDSP (AlBioTech, US) to mannuronan using carbodiimide chemistry. 3.5g (batch 1), and 5g 
(batch 2) of purified mannuronan were dissolved at 1% in phosphate buffer saline (PBS) 
solution overnight. EDC (1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide Hydrochloride) was 
added to the solution at 1:20 molar ratio to the uronic acid monomers of the alginate. Sulfo-
NHS (N-hydroxysulfosuccinimide) was added as a co-reactant to the EDC at a 1:20 molar ratio 
and incubated for 2 hours (h). The peptide was then added at a concentration of 100mol/ml, 
as described in Rowley and Mooney (29) and allowed to react for 20h before the alginate 
solution was purified through extensive dialysis against 3 shifts of distilled water, 3 shifts of 
50mM NaCl, and against distilled water, until the water conductivity measured <2ǋs. The 
alginates were subsequently freeze dried and stored. 
 
2.3. Epimerisation 
Alginate consisting of G- and MG-blocks was made by epimerizing the peptide-coupled 
mannuronans with the mannuronan C-5 epimerase AlgE4 from the alginate producing 
bacterium Hansenula vivelandii (produced recombinantly in Hansenula polymorpha) and AlgE6 
(produced in Eschericia coli) (33). To produce MG alternating alginate, AlgE4 was added to the 
mannuronan at a 1:200 (w/w) ratio in a mixture of 0.25% (w/v) alginate, 50mM MOPS, 2.5mM 
CaCl2 and 10mM NaCl and incubated for 24h-48h at 37ºC. To produce alginates with a G-
content of 50% and 70%, AlgE6 was added to MG alternating alginate at 1:20 ratio in a mixture 
of 0.25% alginate (w/v) and 50mM MOPS for 2.5h and 24h, respectively. To eliminate potential 
toxins, the epimerized alginates were purified through a carbon filter (PALL Corporation).  
Control samples were prepared by epimerizing an uncoupled alginate (i.e. pure mannuronan). 
 
2.4. NMR spectroscopy 
In order to reduce the viscosity of the alginate samples prior to the NMR measurements, the 
samples were depolymerised by mild acid hydrolysis to a final average Dpn~30 residues (38). 
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3-(trimethylsilyl)-proprionic-2,2,3,3,-d4 acid sodium salt (Aldrich, Milwaukee, WI, USA) was 
used as internal standard for the chemical shift and triethylenetetra-amine hexa-acetate (Sigma 
Aldrich) was added to chelate residual calcium ions in end-point epimerased samples. 
Preliminary tests of depolymerisation by mild acid hydrolysis on the peptide grafted alginate 
showed no detachment of the RGD-peptide. 
 
1D and 2D homonuclear experiments were carried out on a BRUKER Avance DPX 300 or 400 
spectrometer equipped with a 5mm QNP and 5mm z-gradient DUL (C/H) probe, respectively.  
2D homonuclear and heteronuclear experiments were performed on a BRUKER Avance 600 
spectrometer equipped with a 5mm z-gradient CP-TCI (H/C/N) probe. The NMR data were 
recorded with BRUKER XwinNMR Ver. 2.6 or 3.5 software. The NMR data were processed and 
analysed with BRUKER Topspin Ver. 3.0 software.  
 
For quantification of the peptide grafted alginate and the M/G ratio in alginate, 1D spectrum 
was recorded using a pulse with a 30 degree flip angle at 25°C, 40ºC, or 90°C. For assignment 
of the peptide and peptide grafted alginate 2D homonuclear in-phase correlation spectroscopy 
(IP-COSY) (39), total correlation spectroscopy (TOCSY), nuclear Overhauser effect spectroscopy 
(NOESY) with mixing time 100ms, and heteronuclear 13C heteronuclear single quantum 
coherence were recorded at 25°C.  
 
2.5. Intrinsic viscosity measurements 
Intrinsic viscosity was measured at the flow time through a capillary, using an Ubbelohde (type 
0a), a titrator (ABU91 Autoburette, Radiometer, Copenhagen), and a viscometer (AVS310, 
Schott Gerte). 10-15mg of alginate were dried in a chemical dehydrator overnight. Alginate was 
dissolved in 10ml water and 10ml 0.1M NaCl.  15ml filtrated 0.1M NaCl were added to a clean 
ubbelohde connected to a viscometer and the efflux time measured at a constant temperature 
of 20°C. After filtration through a 5ǋm filter, 15ml of the alginate solution was added to a clean 
ubbelohde connected to a viscometer, the titrator turned on, and the efflux time measured at a 
constant temperature of 20°C. The sample was diluted 5 times and 4 parallel measurements 
performed at each dilution.  
 
2.6. Cell seeding on flat alginate gels 
To form flat alginate gels, 16.2mM GDL were added to autoclaved solutions of 0.7% alginate, 
2mM HEPES and 8.1mM CaCO3. The solutions were subsequently transferred to 24-well cell 
culture plates (Corning) in volumes of 400l/well and allowed to gel for 1h at room 
temperature. OECs and myoblasts were seeded on the gels at concentrations of 1x104cells/cm2. 
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To compare cell cultures on alginate flat gels with cell cultures on their standard substrates, the 
same concentrations of OECs and myoblats were seeded on empty wells coated with poly-L-
lysine and untreated plastic surface (Corning), respectively. OEC and myoblast cultures were 
fed with appropriate media and incubated at 37ºC with 7% and 5% CO2, respectively. 
 
2.7. Cell encapsulation in alginate beads 
2% (w/v) alginate and 0.3M D-mannitol (VWR) in sterile water were prepared from peptide 
alginates and control alginates. 1.8ml of 2% alginate solution and 0.2ml of cell suspension were 
mixed in a 10ml syringe at a final concentration of 1.5x106 cells/ml of alginate. Beads with 
encapsulated cells were formed by dripping the alginate solutions into a gelling bath containing 
50mM CaCl2, 0.15M Mannitol and 10mM MOPS buffer using an electrostatic bead generator 
with electrostatic potential difference 7kV, flow 10ml/h, and distance between needle and 
gelling solution surface 1.7cm. Beads containing encapsulated myoblasts and OECs were 
transferred to 75cm2 cell culture flasks containing their respective culture media and incubated 
at 37ºC with 5% and 7% CO2, respectively.  
 
2.8. OEC purification and culture 
Neonatal rat OECs were purified as described by Barnett and Roskams (40). Briefly, the 
olfactory bulbs of 4-5 P7 Fischer rats were finely chopped, enzymatically digested in L-15 
(Leibovitz) medium (Sigma) and triturated through a 26 gauge needle. Dissociated cells were 
incubated in a cocktail of the O4 (IgM at 1:4) and anti-galactocerebroside (IgG3 at 1:2.) 
primary antibodies, followed by their fluorochrome conjugated class specific secondary 
antibodies. After rinsing, dissociated cells were incubated in goat anti-mouse IgM phycoerythrin 
and goat anti-mouse IgG3 fluorescein secondary antibodies (1:100, Southern Biotech). OECs 
were purified by fluorescence-activated cell sorting (FACS, Vantage Becton Dickenson) by 
selecting for galactocerebroside-negative and O4-positive cells. Purity of the OEC populations 
was assessed by p75NTR specific labelling and was always 98-100%. OECs were subsequently 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM GlutaMAX; Sigma) with 1.25% 
gentamicin (Sigma) and 5% FBS (Autogen Bioclear) on 13g/ml poly-L-lysine- (PLL) (Sigma) 
coated 25cm2 flasks. The cultures were supplemented with 500ng/ml fibroblast growth factor 2 
(FGF2) (Peprotech, London, UK), 50ng/ml heregulin (hrgǃ1) (R&D Systems Europe Ltd, 
Abingdon, UK), and 10-6 M forskolin (Sigma). The cells were maintained in sub-confluent 
cultures prior to the experiments. 
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2.9. Myoblasts 
C2C12 mouse skeletal myoblasts (ATCC) were cultured in DMEM (Sigma) supplemented with 
10% FCS, 4mM glutamine (Sigma) and 20g/ml gentamicin (Sanofi Aventis). The cells were 
maintained in sub-confluent cultures prior to the experiments.   
 
2.10. Live/Dead assay 
Cell viability was qualitatively assessed post-seeding/encapsulation by visualisation of live and 
dead cells, stained by calcein and ethidium homodimer-1 (EthD-1) using LIVE/DEAD® assay 
(Molecular Probes).  A working solution consisting of 3ml PBS, 1.8l calcein and 8l EthD-1 was 
freshly made before each experiment and added to cell culture media in a 1:1 ratio. The 2D 
cultures and 3D cultures were studied using confocal laser scanning microscopy (CLSM) 
(LSM510, Carl Zeiss).  Three-dimensional images were constructed by a 3D projection function 
after digital sectioning through the entire microbeads (Z-stacks). A quantitative assessment of 
the relative proportion of live and dead cells was performed by counting live and dead cells 
through the Z-stacks obtained from the microbeads (n=10).  
2.11. MTT assay 
Mitochondrial activity was assessed by MTT assay. Cell cultures on flat alginate gels ore 
encapsulated cells were incubated with culture media conditioned with 0.5mg/ml MTT for 4h at 
37ºC. For the flat gels, the media was harvested and cells sampled by centrifugation. 
Subsequently, 400ǋl DMSO and 50ǋl 0.1M glycine/0.1M NaCl were added to the cell pellets. For 
the microbeads, the media were removed and further processes as described (41). For each 
condition, 200ǋl of the colour solution were analysed at 570nm on a Victor3 Multilabel Plate 
Reader (Perkin Elmer).  
 
3. Results 
 
3.1. Characterisation of modified alginates 
Coupling of RGD-peptide (GRGDSP) to mannuronan was characterised by NMR spectroscopy 
using homo- and heteronuclear spectra (Figure 1). The anomeric signals for mannuronan and 
both Hǃ, HǄ from proline and arginine were used to determine the degree of substituted C-5 
mannuronan units with RGD peptide. Due to relatively large differences in concentration 
between mannuronan and RGD-peptide, which resulted in a high signal-to-noise ratio in 
combination with complex coupling for the peptide proton, this will only give a rough estimate 
for the specific coupling reaction. The NMR spectra also revealed some by-products from the 
coupling reaction which, based on NMR spectra, could be assigned to urea derivatives and N-
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acylurea bound to mannuronan. The remaining urea derivatives were removed during the 
activated carbon filtration, while the N-acylurea was still bound to the alginate. A negative 
control experiment with N-acylurea-bound alginate did not show any effects on viability and 
morphology of OECs in 2D culture. Prior to the coupling of RGD-peptide to mannuronan, both 
compounds were characterised using standard 1D and 2D homonuclear spectra in order to 
check their purity (data not shown). 
 
NMR spectroscopy was also used to determine the composition of the alginates as previously 
described (34). Figure 2 shows the anomeric regions of alginate before and after epimerisation. 
From the spectra, we calculated the molar fractions of monomers, the four possible diads (FGG, 
FMM, FMG, FGM), and the G-centered triads (FGGG, FMGG, and FGGM and FMGG), which allow 
calculation of the average length of the G-blocks (NG>1), a value that correlates well with the gel 
forming capacity of the polymers. The sequence data, the peptide content, and intrinsic viscosities 
are provided in Table 1. The epimerisation reactions were tailored to produce alginates 
containing alternating structures of M and G interspacing G-blocks. Indeed, high-G and low-G 
alginates with and without peptides were produced in both batches of alginates for 2D and 3D 
experiments. As can be seen for the alginates produced for 2D experiments, the FMM was lower 
than for the naturally occurring alginate used as controls. Hence, about every second M was 
converted to G by the AlgE4 epimerase. For the alginates produced for the 3D experiments, the 
conversion of M-blocks to MG-blocks is not that obvious, indicating inefficient treatment of the 
mannuronan by AlgE4. However, the efficiency of AlgE6 is shown given that long G-blocks 
(NG>12) were produced for all high-G samples. As described above, the peptide content was 
estimated by NMR spectroscopy to be about 0.2% and 0.1% of the uronic acid units grafted 
with peptide for the 2D and 3D experiments, respectively. As expected, the content of peptide 
was the same within each batch, as the same background (i.e. mannuronan with peptide) was 
used for the production of epimerised alginates. The grafted peptide did not seem to affect the 
epimerisation reaction as a higher G-content (FG) was found for the peptide grafted alginates 
compared to the non-grafted alginates. Table 1 also shows that a slight reduction in intrinsic 
viscosity was seen for all samples compared to the mannuronan starting material, probably as a 
result of handling and hydrolysis. 
 
3.2. Interactions between alginates and OECs  
 
3.2.1. Flat gels 
Microscopic examination of the OEC 2D cultures after Live/Dead staining revealed distinct 
morphological differences in OECs contingent on the type of substrate used (Figure 3). On the 
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RGD substituted alginates, i.e. RGD LG and RGD HG, the OECs hade formed small clusters and 
they  were rounded, with short bipolar processes attached to the gel surface. By contrast, OECs 
seeded on the non-substituted alginates, i.e. Alg LG, Alg HG, and UPLVG, were spherical and 
had formed aggregates floating in the culture media, These cells demonstrated poor survival, 
with all cells being lost, especially those cultured on UPLVG gels, by 72h post-seeding. Control 
OEC cultures on PLL-treated surfaces displayed normal morphology, i.e. the majority of cells 
were spindle-shaped, interspersed with some stellate-shaped cells.  
 
The mitochondrial activity of OECs cultured on different substrates was assessed between 24h 
and 72h post-seeding. Irrespective of type of alginate substrate, the mitochondrial activity of 
OECs decreased by 48h, possibly reflecting a relatively low attachment ratio. An increase in 
mitochondrial activity was observed, however, for OECs cultured on PLL-coated surfaces, 
consistent with better attachment and survival.  
 
3.2.2. Microbeads 
 
Live/Dead assay on encapsulated OECs (3D cultures) showed that the cells were able to survive 
within the microbeads, irrespective of alginate type or modification used. Interestingly, OECs 
encapsulated in the coupled as well as non-coupled alginates had arranged themselves within 
channels formed in the alginate in a characteristic fireworks-like pattern. The relative 
proportions of live cells/microbead were estimated from digital sectioning through the 
microbeads (Z-stacks) using CLSM. Overall OEC survival, however, inside the microbeads 
deteriorated between 9d and 16d post-encapsulation (Figure 3).  
 
3.3. Interactions between alginates and C2C12 myoblasts 
3.3.1. Flat gels  
 
Microscopic examination of the C2C12 myoblasts cultured on RGD-coupled alginate , i.e. RGD 
LG, RGD HG, small clusters of cells (Figure 4). Similar to OECs, the myoblasts were rounded 
and extended protrusions attached to the gel surface. However, no myoblast attachment was 
observed on the non-coupled alginates, i.e. Alg LG, Alg HG, and UPLVG). Instead, large cell 
aggregates were observed, floating in the media (Figure 4). On cell culture plastic, however, 
the myoblasts were attached and spread across the gel surface (Figure 4).  
 
The mitochondrial activity of myoblasts was higher when cultured on the RGD-coupled 
alginates, compared to non-coupled ones. For myoblasts cultured on RGD HG, the 
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mitochondrial activity was consistent during the 72h period, compared to decreasing 
mitochondrial activity observed on the RGD LG gels. The highest levels of mitochondrial activity 
though were observed on myoblasts on cell culture plastic (Figure 4).  
 
3.3.2. Microbeads 
Live/Dead assay demonstrated long-term myoblast survival throughout the observation period 
(41d), irrespective of type of alginate used for the 3D cultures, although dead cells were also 
observed in the microbeads (Figure 4). Similar to OECs, myoblasts cultured in RGD LG and Alg 
LG had arranged themselves within channels, showing a distinct fireworks-like pattern.  While 
mostly dead cells were observed in these channels at 1d-10d, the channels were subsequently 
filled with live myoblasts. 
 
The mitochondrial activity of myoblasts encapsulated in RGD-coupled (RGD HG, RGD LG, 
batch1) and non-coupled (Alg HG, Alg LG, and UPLVG) alginates was monitored over a period 
of 38d. At 1d-14d post-encapsulation, The mitochondrial activity of myoblasts in RGD HG and 
Alg HG alginates was lower than in RGD LG, Alg LG, and UPLVG.  After 20d, the mitochondrial 
activity of myoblasts ad increased in all types of microbeads. Compared to unmodified 
alginates, the RGD-modified alginates did not seem to impact myoblast viability in the 3D 
cultures, rather the differences observed seem to relate more to the M and G content of the 
alginates.  
 
DISCUSSION
Although there is intense interest in peptide coupled alginates in the field of tissue engineering 
and an increasing number of studies are using RGD-coupled alginates (REFs), little has been 
described regarding the composition of the polymers utilised in these studies. Hence, the aim of 
this study was to monitor cell attachment and survival using structurally-designed and well-
characterised RGD-coupled alginates. The peptide alginates were produced by chemoenzymatic 
modification, ensuring peptide coupling to the M-units in the alginate by first introducing 
peptide to mannuronan and subsequently introducing MG- and G-blocks by epimerisation. In 
this way, the peptide coupling on the carboxyl group of the uronic acids does not interfere with 
G-blocks being the main contributor to alginate gel formation. This chemoenzymatic strategy 
has previously been shown for galactose (36) and methacrylate substituted alginates (32).  
 
The peptide coupling was characterised by NMR showing that 0.1-0.2% of the monomers were 
substituted by peptide. As 5% of the carboxyl groups were activated by EDC and Sulfo-NHS, 
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and excess of peptide was added, the yield is 2-4%. The basis of this coupling reaction was the 
work of Rawley and Mooney (29), reporting 55-60% incorporation efficiency using carbodiimide 
chemistry. Even though the results from the NMR characterisation are a rough estimate, this 
cannot explain the difference in the coupling efficiency (29). Furthermore, NMR spectroscopy 
allows identification of other products from the carbodiimide coupling reaction. This information 
was used to adapt downstream protocols for processing of the RGD-coupled alginate. 
Especially, some of the by-products and non-reacted peptides were not removed during 
dialysis. This can lead to an apparently higher incorporation efficiency. The NMR data show that 
the active coal filtration was efficient to remove most of these products from RGD-coupled 
alginates, except for N-acylurea bound to alginate. Nonetheless, it can be concluded that NMR 
spectroscopy can be used to determine the coupling efficiency, as well as to monitor the effects 
of the downstream process on the RGD-coupled alginates. 
 
In addition to the above, NMR was used to characterise alginate composition. The relevant 
findings were consistent with what is previously shown for enzymatic modifications of 
mannuronan with the mannuronan C-5 epimerases AlgE4 and AlgE6 (33,34). The alginate was 
tailored to contain a majority of G- and MG-blocks forming stable gels with divalent ions (33). 
Furthermore, we aimed to produce alginates with different contents of G-blocks, as this has 
been demonstrated to give gels of different stiffness (34), which has been shown to impact 
differentiation of C2C12 myoblasts (29). As expected, compared to UPLVG alginate, the 
epimerized alginates had a reduced fraction of M dimers and trimers and a higher number of 
MG-blocks. Furthermore, FMM values in peptide coupled and non-coupled equivalents were 
similar, indicating that the peptide did not significantly interrupt the epimerization reaction at a 
degree of substitution of 0.1%-0.2%.   
 
Compared to batch 2, epimerised alginates in batch 1 had similar FG values, and showed better 
homology between the RGD-coupled alginates and their non-coupled equivalents. However, 
while batch 2 alginates had similar FG values, the G-content in the RGD LG and Alg LG alginates 
was much lower than that of the LG alginates in batch 1 (i.e. FG §0.3, compared to FG §0.5). 
This difference in the G-content can be explained by the fact that the reaction time for batch 2 
alginates was 24h, as opposed to 48h used for batch 1.  Thus the stability of batch 1 alginate 
gels should be expected to be higher than that of batch 2 alginates given that substituting M-
blocks with MG-blocks has been shown to produce more stable alginates (33, 34, 42). 
 
The intrinsic viscosity of the alginates was found to decrease slightly during peptide coupling 
and epimerization.  Vold et al (43) showed that there are no differences in chain stiffness 
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between poly M, poly G, and poly MG alginates.  The coupling and epimerization reactions per 
se do not result in chain breakage, however a degree of hydrolysis upon handling of the gels 
may explain the observed reduction in viscosity.  Nonetheless, intrinsic viscosity values, 
irrespective of sample type, are comparable. 
 
Subsequent to characterization, we proceeded to test the interactions of the modified alginates 
with OECs and myoblasts, two different cell types with therapeutic potential in regenerative 
medicine and tissue engineering.   
 
OECs are unique glia that have emerged as promising candidates in the repair of CNS lesions 
(37, 44, 45), however, OEC survival post-transplantation may be expected to be as low as 50% 
(44). Despite the fact that encapsulation of OECs in biopolymer matrices may improve cell 
survival, few studies have explored this line of research (46, 47), while, to our knowledge, there 
is only one study of OEC culture on alginate (48). The specific study utilised unmodified alginate 
alone, and in combination with fibronectin, for culture of OEC monolayers and showed that 
OECs were transformed to atypical cells and displayed inhibited metabolic activity (48).  
 
In our study, OECs cultured on RGD alginate flat gels formed large clusters of spherical cells 
with bipolar protrusions attached to the gels. The particular morphotype was similar to that of 
myoblasts cultured on RGD alginates, and also consistent with a previous report, in which OEC 
morphologic plasticity and motility were associated with rapid changes in mitotic activity (49).  
There were no obvious differences in OEC morphology and pattern between RGD LG and RGD 
HG alginates, suggesting that while the RGD peptide may facilitate OEC adhesion, gel rigidity 
does not inhibit or promote OEC attachment.  
 
The above observations indicate that the presence of RGD in the alginate, induced an effect to 
the OEC 2D cultures in terms of cell-cell, cell-substrate interactions. It can be argued that the 
specific morphology and pattern observed in OEC cultured on RGD-coupled alginate gels are 
indicative of a dynamic intracellular response in terms of altered gene/protein expression, 
transcription and translation, causing a modulation of cytoskeletal structure. It would be 
interesting to elucidate which factors in OECs are upregulated and downregulated in response 
to RGD-coupled alginates, however, such investigations would necessitate the use of proteomic 
and/or genomic methods and were, therefore, beyond the scope of the present study.  
 
Encapsulation of OECs in RGD-coupled alginates (3D cultures) did not induce an effect on OECs 
in terms of improved survival. This suggests that further modifications may be required to 
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develop a tailor-made alginate substrate for optimisation of OEC function and survival with 
regard to future transplantation studies. Such modifications may include coupling more RGD-
peptide to the alginate, further modulating the mechanics of the alginate microbeads, as well as 
testing whether higher concentrations of encapsulated OECs may display improved survival.  
 
Myoblasts are proposed for repair of skeletal muscle and myocardial tissue (50, 51) and have 
been widely used in conjunction with biopolymer matrices (32, 50, 51, 52). Rowley and Mooney 
(29) have established that RGD alginates mediate myoblast differentiation into multi-nucleated 
myofibrils. In our study, however, we were not able to replicate these findings as the myoblasts 
remained undifferentiated, displaying unaltered morphology throughout the observation period.  
The lack of differentiation may be attributed to the fact that the RGD densities in our alginates 
were significantly lower than those used by Rowley and Mooney (29). However, control 
myoblast cultures, using plastic as a substrate, supplemented with differentiation media, also 
remained undifferentiated in this experiment.  Therefore, we cannot exclude the possibility that 
the myoblasts utilized in this study had lost their differentiation capacity.  
 
There was a discrepancy between the low mitochondrial activity of myoblasts encapsulated in 
RGD HG and Alg HG alginates and the relatively large proportion of live cells observed in these 
microbeads during the first week after encapsulation. The comparatively low metabolic activity 
may have denoted a differentiation process, however, CLSM observations did not confirm any 
signs of cell fusion.   
 
The overall survival/growth of the myoblasts during the 42d observation period showed only 
small differences in mitochondrial activity as well as the proportion of live and dead cells within 
the Alg HG and UPLVG microbeads. We interpret these findings as indicative of 1-2 cell divisions 
during the 41d encapsulation period, as shown previously (32).   
 
It is noteworthy that relatively improved myoblast survival was observed in the RGD LG and Alg 
LG microbeads, where the cells had arranged themselves in a characteristic fireworks-like 
pattern inside channels formed inside the microbead.  The channels formed in the microbeads 
could be attributed to viscous drag that may have occurred during gelling. Myoblasts, have 
been previously shown to have inhibited growth after encapsulation (32, 52). Our observations 
thus indicate that myoblasts may have been able to expand within these channels, which are 
assumed to contain lower gel concentrations, or may even represent gel-free pockets. 
Interestingly, there is a better correlation between MTT data and Live/Dead CLSM data from 
the LG alginate microbeads throughout the observation period, compared to the other alginate 
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types.  Furthermore, the overall metabolic activity of myoblasts encapsulated in the LG 
alginates was consistently higher than that of myoblasts in HG and UPLVG alginates.  It is 
known that increased solid stress on cells may affect proliferation and survival (41). On the 
other hand, a higher level of capsule stability in terms of increased G-content may be desirable 
with a view to in vivo transplantation (53). Our findings suggest, however, that a lower degree 
of network rigidity, rather than grafting the alginates with RGD peptide alone, may be a key 
component for improved myoblast survival post-encapsulation in vitro. 
 
Taken together, the findings from the myoblast and OEC 2D and 3D studies did not reveal 
enhanced cell adhesion and survival in vitro as a result of RGD grafting, despite observed 
attachment of cells, morphological changes and partially improved viability in 2D cultures for 
some of the surfaces . Nonetheless, we predict that improved attachment and survival of OECs 
and myoblasts should be achieved with higher percentage of coupled peptides in the alginates. 
We also recognise that further modifications and tailoring of the alginates may be required with 
a view to transplantation of encapsulated OECs and myoblasts in vivo, especially with regard to 
the former as little is known about OEC interactions with modified alginates. Furthermore, given 
that different types of CNS lesions require different reparative strategies, it is important to 
consider that the alginate substrates used in conjunction with OEC transplantation need to be 
tailored accordingly. For example, if OEC transplantation aims at neuroprotection, as in the case 
of intravitreal grafts to promote optic nerve regeneration after injury, optimisation of OEC 
survival and function post-transplantation, in terms of sustained secretion of neurotrophic 
factors, may be effected by encapsulation and associated changes in the 3D microenvironment 
of the cells.  If, however, OEC transplants aim to stimulate directed axonal growth towards 
synaptic targets distal to the lesion site, as for example in a spinal cord injury scenario, an 
appropriate RGD-coupled alginate matrix should be in the form of a scaffold which, should 
serve the dual purpose of mediating improved function and survival of seeded OECs, as well as 
providing an appropriate substrate for regenerating RGC axons in terms of structural and 
molecular support, by mimicking ECM functions. Finally, other types of CNS lesions, such as 
stroke-induced cavities, might require transplantation of microbeads with cells seeded on the 
surface, to act as scaffolds and induce de novo neurogenesis within the lesion cavity (54). The 
importance of unique strategies for alginate modification as well as appropriate characterisation 
of the modified alginates are of great relevance in this context. 
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Figure 1 
 
 
Figure 1 - 1D proton spectrum RGD-peptide grafted mannuronan at 40 qC. A. The anomeric 
region. B. The aliphatic region. The anomeric proton of mannuronan and both HE, HJ from 
proline and arginine were used to determine the degree of substituted C-5 mannuronic acid 
units with RGD-peptide. By-products were assigned to consist mainly of urea derivatives and N-
acylurea bound to mannuronan. C. The aliphatic region before activated coal treatment D. The 
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aliphatic region after the activated coal treatment. The chemical shifts vary slightly given the 
equal pH of the samples. Acetate was an impurity from the freeze dryer. 
 
Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 - 1D proton spectrum of epimerased RGD-peptide grafted alginate at 90 qC. A. The 
anomeric region for the RGD-peptide grafted alginate before epimerisation B. after 
epimerasation.   
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Figure 3 
 
 
 
 
 
 
Figure 3 - Live/dead assay showing overall OEC survival and interaction profiles with different 
alginate substrates. A. Representative images of 2D ad 3D cultures. Upper row shows 2D OEC 
cultures at 6d post-seeding. OECs seeded on RGD-modified alginates display altered 
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morphology compared to controls (PLL substrate). Instead of spindle shaped, the cells are 
rounded and extend bipolar protrusions attached to the gel surface (shown in higher 
magnification in B). Second and fourth rows show representative images from Live/Dead assays 
on 3D OEC cultures at 6d and 16d. Overall OEC survival declines between 6d and 16d, 
irrespective of substrate. Equator images, representing cross sections through the different 
types of alginate microbeads at the same time points, show that the size of the microbeads is 
stable over time. C Higher magnification of RGD LG microbeads at 6d post-encapsulation 
showing characteristic arrangement of OECs in a fireworks-like pattern.  
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Figure 4 - Interaction profiles of myoblasts with different alginate substrates. A. 
Representative images of 2D ad 3D cultures. Upper row shows 2D myoblast cultures at 48h 
post-seeding. Myoblasts seeded on RGD-modified alginates display altered morphology 
compared to controls (plastic substrate). The myoblasts are rounded and extend bipolar 
protrusions attached to the gel surface (shown in higher magnification in B). Second to sixth 
row showing Live/Dead assay from 3D myoblast cultures at 1d, 10d, and 38d post-
encapsulation. Relatively improved myoblast survival was observed in the RGD LG (shown in 
higher magnification in C) and Alg LG microbeads, where the cells had arranged themselves in 
a characteristic fireworks-like pattern inside channels formed inside the microbead. Equator 
images from the three different time points demonstrate that the different types of microbeads 
were stable throughout the observation period. D, E show mitochondrial activity of myoblasts 
from the 2D and 3D cultures respectively. The overall survival/growth of the myoblasts during 
the observation period showed only small differences in mitochondrial activity as well as in the 
proportion of live and dead cells within the Alg HG and UPLVG microbeads.  
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